{ "version": "2.2", "instance": { "moln-20251231.htm": { "nsprefix": "moln", "nsuri": "http://www.molecularpartners.com/20251231", "dts": { "inline": { "local": [ "moln-20251231.htm" ] }, "schema": { "local": [ "moln-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd", "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "calculationLink": { "local": [ "moln-20251231_cal.xml" ] }, "definitionLink": { "local": [ "moln-20251231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "moln-20251231_lab.xml" ] }, "presentationLink": { "local": [ "moln-20251231_pre.xml" ] } }, "keyStandard": 297, "keyCustom": 124, "axisStandard": 29, "axisCustom": 2, "memberStandard": 42, "memberCustom": 39, "hidden": { "total": 10, "http://www.molecularpartners.com/20251231": 6, "http://xbrl.sec.gov/dei/2025": 4 }, "contextCount": 289, "entityCount": 1, "segmentCount": 87, "elementCount": 770, "unitCount": 11, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 965, "http://xbrl.sec.gov/dei/2025": 47, "http://xbrl.sec.gov/cyd/2025": 15, "http://xbrl.sec.gov/ecd/2025": 1 }, "report": { "R1": { "role": "http://www.molecularpartners.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.molecularpartners.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorFirmId", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition", "longName": "9952151 - Statement - Consolidated Statement of Financial Position", "shortName": "Consolidated Statement of Financial Position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:NoncurrentAssets", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R4": { "role": "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult", "longName": "9952152 - Statement - Consolidated Statement of Profit or Loss and Other Comprehensive Result", "shortName": "Consolidated Statement of Profit or Loss and Other Comprehensive Result", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLossFromOperatingActivities", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R5": { "role": "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows", "longName": "9952153 - Statement - Consolidated Statement of Cash Flows", "shortName": "Consolidated Statement of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ProfitLoss", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R6": { "role": "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "longName": "9952154 - Statement - Consolidated Statement of Changes in Equity", "shortName": "Consolidated Statement of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-10", "name": "ifrs-full:Equity", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "ifrs-full:Equity", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R7": { "role": "http://www.molecularpartners.com/role/Generalinformation", "longName": "9952155 - Disclosure - General information", "shortName": "General information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.molecularpartners.com/role/Summaryofmaterialaccountingpolicies", "longName": "9952156 - Disclosure - Summary of material accounting policies", "shortName": "Summary of material accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.molecularpartners.com/role/Financialriskmanagement", "longName": "9952157 - Disclosure - Financial risk management", "shortName": "Financial risk management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://www.molecularpartners.com/role/Accountingestimatesandjudgments", "longName": "9952158 - Disclosure - Accounting estimates and judgments", "shortName": "Accounting estimates and judgments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.molecularpartners.com/role/Revenueandentitywidedisclosures", "longName": "9952159 - Disclosure - Revenue and entity-wide disclosures", "shortName": "Revenue and entity-wide disclosures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.molecularpartners.com/role/Propertyplantandequipment", "longName": "9952160 - Disclosure - Property, plant and equipment", "shortName": "Property, plant and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.molecularpartners.com/role/Intangibleassets", "longName": "9952161 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.molecularpartners.com/role/Financialinstruments", "longName": "9952162 - Disclosure - Financial instruments", "shortName": "Financial instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.molecularpartners.com/role/Othercurrentassets", "longName": "9952163 - Disclosure - Other current assets", "shortName": "Other current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.molecularpartners.com/role/Tradeandotherreceivables", "longName": "9952164 - Disclosure - Trade and other receivables", "shortName": "Trade and other receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.molecularpartners.com/role/Cashandcashequivalentsandshorttermtimedeposits", "longName": "9952165 - Disclosure - Cash and cash equivalents and short-term time deposits", "shortName": "Cash and cash equivalents and short-term time deposits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.molecularpartners.com/role/Shareholdersequity", "longName": "9952166 - Disclosure - Shareholders\u2019 equity", "shortName": "Shareholders\u2019 equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.molecularpartners.com/role/Tradeandotherpayables", "longName": "9952167 - Disclosure - Trade and other payables", "shortName": "Trade and other payables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.molecularpartners.com/role/Accruedexpenses", "longName": "9952168 - Disclosure - Accrued expenses", "shortName": "Accrued expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.molecularpartners.com/role/Contractliability", "longName": "9952169 - Disclosure - Contract liability", "shortName": "Contract liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.molecularpartners.com/role/Additionalinformationonthenatureofexpenses", "longName": "9952170 - Disclosure - Additional information on the nature of expenses", "shortName": "Additional information on the nature of expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.molecularpartners.com/role/Royaltiesandlicensefees", "longName": "9952171 - Disclosure - Royalties and license fees", "shortName": "Royalties and license fees", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfRoyaltiesAndLicenseFeesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfRoyaltiesAndLicenseFeesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.molecularpartners.com/role/Personnelexpenses", "longName": "9952172 - Disclosure - Personnel expenses", "shortName": "Personnel expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.molecularpartners.com/role/Financialincomeandfinancialexpense", "longName": "9952173 - Disclosure - Financial income and financial expense", "shortName": "Financial income and financial expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.molecularpartners.com/role/IncomeTaxes", "longName": "9952174 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.molecularpartners.com/role/Earningspershare", "longName": "9952175 - Disclosure - Earnings per share", "shortName": "Earnings per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.molecularpartners.com/role/Leases", "longName": "9952176 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.molecularpartners.com/role/Relatedpartydisclosures", "longName": "9952177 - Disclosure - Related party disclosures", "shortName": "Related party disclosures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.molecularpartners.com/role/Capitalcommitments", "longName": "9952178 - Disclosure - Capital commitments", "shortName": "Capital commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.molecularpartners.com/role/Financialriskmanagement_1", "longName": "9952179 - Disclosure - Financial risk management", "shortName": "Financial risk management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://www.molecularpartners.com/role/Restructuringexpense", "longName": "9952180 - Disclosure - Restructuring expense", "shortName": "Restructuring expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfRestructuringExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfRestructuringExpenseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.molecularpartners.com/role/Eventsafterthebalancesheetdate", "longName": "9952181 - Disclosure - Events after the balance sheet date", "shortName": "Events after the balance sheet date", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R34": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R35": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies", "longName": "9955511 - Disclosure - Summary of material accounting policies (Policies)", "shortName": "Summary of material accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesTables", "longName": "9955512 - Disclosure - Summary of material accounting policies (Tables)", "shortName": "Summary of material accounting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R38": { "role": "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresTables", "longName": "9955513 - Disclosure - Revenue and entity-wide disclosures (Tables)", "shortName": "Revenue and entity-wide disclosures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.molecularpartners.com/role/PropertyplantandequipmentTables", "longName": "9955514 - Disclosure - Property, plant and equipment (Tables)", "shortName": "Property, plant and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.molecularpartners.com/role/IntangibleassetsTables", "longName": "9955515 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.molecularpartners.com/role/FinancialinstrumentsTables", "longName": "9955516 - Disclosure - Financial instruments (Tables)", "shortName": "Financial instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.molecularpartners.com/role/OthercurrentassetsTables", "longName": "9955517 - Disclosure - Other current assets (Tables)", "shortName": "Other current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.molecularpartners.com/role/TradeandotherreceivablesTables", "longName": "9955518 - Disclosure - Trade and other receivables (Tables)", "shortName": "Trade and other receivables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsTables", "longName": "9955519 - Disclosure - Cash and cash equivalents and short-term time deposits (Tables)", "shortName": "Cash and cash equivalents and short-term time deposits (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.molecularpartners.com/role/ShareholdersequityTables", "longName": "9955520 - Disclosure - Shareholders' equity (Tables)", "shortName": "Shareholders' equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.molecularpartners.com/role/TradeandotherpayablesTables", "longName": "9955521 - Disclosure - Trade and other payables (Tables)", "shortName": "Trade and other payables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.molecularpartners.com/role/AccruedexpensesTables", "longName": "9955522 - Disclosure - Accrued expenses (Tables)", "shortName": "Accrued expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesTables", "longName": "9955523 - Disclosure - Additional information on the nature of expenses (Tables)", "shortName": "Additional information on the nature of expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.molecularpartners.com/role/PersonnelexpensesTables", "longName": "9955524 - Disclosure - Personnel expenses (Tables)", "shortName": "Personnel expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseTables", "longName": "9955525 - Disclosure - Financial income and financial expense (Tables)", "shortName": "Financial income and financial expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.molecularpartners.com/role/IncomeTaxesTables", "longName": "9955526 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.molecularpartners.com/role/EarningspershareTables", "longName": "9955527 - Disclosure - Earnings per share (Tables)", "shortName": "Earnings per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.molecularpartners.com/role/LeasesTables", "longName": "9955528 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.molecularpartners.com/role/RelatedpartydisclosuresTables", "longName": "9955529 - Disclosure - Related party disclosures (Tables)", "shortName": "Related party disclosures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.molecularpartners.com/role/FinancialriskmanagementTables", "longName": "9955530 - Disclosure - Financial risk management (Tables)", "shortName": "Financial risk management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesSegmentReportingDetails", "longName": "9955531 - Disclosure - Summary of material accounting policies - Segment Reporting (Details)", "shortName": "Summary of material accounting policies - Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "moln:NumberOfOperatingSegments1", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:NumberOfOperatingSegments1", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails", "longName": "9955532 - Disclosure - Summary of material accounting policies - Disclosure of Useful Lives of Property, Plant and Equipment (Details)", "shortName": "Summary of material accounting policies - Disclosure of Useful Lives of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-37", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-37", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesIntangibleAssetsDetails", "longName": "9955533 - Disclosure - Summary of material accounting policies - Intangible Assets (Details)", "shortName": "Summary of material accounting policies - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-40", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-40", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails", "longName": "9955534 - Disclosure - Summary of material accounting policies - Employee Benefits (Details)", "shortName": "Summary of material accounting policies - Employee Benefits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "moln:PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails", "longName": "9955535 - Disclosure - Revenue and entity-wide disclosures - Narrative (Details)", "shortName": "Revenue and entity-wide disclosures - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-44", "name": "moln:ResearchAndDevelopmentExpenseReimbursement", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R61": { "role": "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyCountryDetails", "longName": "9955536 - Disclosure - Revenue and entity-wide disclosures - Disclosure of Revenue by Country (Details)", "shortName": "Revenue and entity-wide disclosures - Disclosure of Revenue by Country (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-50", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R62": { "role": "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails", "longName": "9955537 - Disclosure - Revenue and entity-wide disclosures - Disclosure of Revenue by Major Alliance Partner (Details)", "shortName": "Revenue and entity-wide disclosures - Disclosure of Revenue by Major Alliance Partner (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-53", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R63": { "role": "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails", "longName": "9955538 - Disclosure - Property, plant and equipment (Details)", "shortName": "Property, plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R64": { "role": "http://www.molecularpartners.com/role/IntangibleassetsDetails", "longName": "9955539 - Disclosure - Intangible assets (Details)", "shortName": "Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-133", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R65": { "role": "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails", "longName": "9955540 - Disclosure - Financial instruments - Disclosure of Financial Assets at Amortized Cost (Details)", "shortName": "Financial instruments - Disclosure of Financial Assets at Amortized Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-143", "name": "ifrs-full:FinancialAssets", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-143", "name": "ifrs-full:FinancialAssets", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfFinancialAssetsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails", "longName": "9955541 - Disclosure - Financial instruments - Disclosure of Financial Liabilities at Amortized Cost (Details)", "shortName": "Financial instruments - Disclosure of Financial Liabilities at Amortized Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-153", "name": "ifrs-full:FinancialLiabilities", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-153", "name": "ifrs-full:FinancialLiabilities", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.molecularpartners.com/role/OthercurrentassetsDetails", "longName": "9955542 - Disclosure - Other current assets (Details)", "shortName": "Other current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:CurrentPrepaidExpenses", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:CurrentPrepaidExpenses", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails", "longName": "9955543 - Disclosure - Trade and other receivables - Disclosure of Detailed Information about Trade and Other Receivables (Details)", "shortName": "Trade and other receivables - Disclosure of Detailed Information about Trade and Other Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:CurrentValueAddedTaxReceivables", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R69": { "role": "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails", "longName": "9955544 - Disclosure - Trade and other receivables - Disclosure of Trade Receivables Denominated in Other Currency Explanatory (Details)", "shortName": "Trade and other receivables - Disclosure of Trade Receivables Denominated in Other Currency Explanatory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "moln:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R70": { "role": "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails", "longName": "9955545 - Disclosure - Cash and cash equivalents and short-term time deposits - Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits (Details)", "shortName": "Cash and cash equivalents and short-term time deposits - Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "moln:DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R71": { "role": "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsNarrativeDetails", "longName": "9955546 - Disclosure - Cash and cash equivalents and short-term time deposits - Narrative (Details)", "shortName": "Cash and cash equivalents and short-term time deposits - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-161", "name": "moln:NumberOfShortTermTimeDepositPositions", "unitRef": "position", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "moln:NumberOfShortTermTimeDepositPositions", "unitRef": "position", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails", "longName": "9955547 - Disclosure - Shareholders\u2019 equity - Narrative (Details)", "shortName": "Shareholders\u2019 equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:Equity", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:ParValuePerShare", "unitRef": "chfPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R73": { "role": "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails", "longName": "9955548 - Disclosure - Shareholders' equity - Shares Issued (Details)", "shortName": "Shareholders' equity - Shares Issued (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "moln:NumberOfSharesIssuedInCapitalRaiseEquity", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R74": { "role": "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails", "longName": "9955549 - Disclosure - Shareholders' equity - Disclosure of Treasury Shares (Details)", "shortName": "Shareholders' equity - Disclosure of Treasury Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-35", "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "unitRef": "chfPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R75": { "role": "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails", "longName": "9955550 - Disclosure - Trade and other payables - Disclosure of Detailed Information about Trade and Other Payables (Details)", "shortName": "Trade and other payables - Disclosure of Detailed Information about Trade and Other Payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R76": { "role": "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails", "longName": "9955551 - Disclosure - Trade and other payables - Disclosure of Trade Payables Denominated in Other Currency Explanatory (Details)", "shortName": "Trade and other payables - Disclosure of Trade Payables Denominated in Other Currency Explanatory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-161", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R77": { "role": "http://www.molecularpartners.com/role/AccruedexpensesDetails", "longName": "9955552 - Disclosure - Accrued expenses (Details)", "shortName": "Accrued expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-5", "name": "moln:CurrentAccruedProjectCostsAndRoyalties", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "moln:CurrentAccruedProjectCostsAndRoyalties", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "moln:DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.molecularpartners.com/role/ContractliabilityDetails", "longName": "9955553 - Disclosure - Contract liability (Details)", "shortName": "Contract liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:NoncurrentContractLiabilities", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "ifrs-full:NoncurrentContractLiabilities", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "longName": "9955554 - Disclosure - Additional information on the nature of expenses (Details)", "shortName": "Additional information on the nature of expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:EmployeeBenefitsExpense", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-182", "name": "moln:ResearchConsumablesAndExternalResearchAndDevelopmentExpense", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R80": { "role": "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails", "longName": "9955555 - Disclosure - Royalties and license fees (Details)", "shortName": "Royalties and license fees (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-191", "name": "moln:RoyaltiesMinimumAnnualAmountTotal", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-191", "name": "moln:RoyaltiesMinimumAnnualAmountTotal", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails", "longName": "9955556 - Disclosure - Personnel expenses - Disclosure of Detailed Information about Employee Expenses (Details)", "shortName": "Personnel expenses - Disclosure of Detailed Information about Employee Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:WagesAndSalaries", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:WagesAndSalaries", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails", "longName": "9955557 - Disclosure - Personnel expenses - Disclosure of Detailed Information about Employee Head Count (Details)", "shortName": "Personnel expenses - Disclosure of Detailed Information about Employee Head Count (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "moln:AverageNumberOfFullTimeEquivalentEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "1", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:AverageNumberOfFullTimeEquivalentEmployees", "unitRef": "employee", "xsiNil": "false", "lang": "en-US", "decimals": "1", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails", "longName": "9955558 - Disclosure - Personnel expenses - Disclosure of Net Defined Benefit Liability (Asset) (Details)", "shortName": "Personnel expenses - Disclosure of Net Defined Benefit Liability (Asset) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:ActuarialAssumptionOfDiscountRates", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R84": { "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "longName": "9955559 - Disclosure - Personnel expenses - Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income (Details)", "shortName": "Personnel expenses - Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": null }, "R85": { "role": "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "longName": "9955560 - Disclosure - Personnel expenses - Additional Information (Details)", "shortName": "Personnel expenses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-224", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R86": { "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails", "longName": "9955561 - Disclosure - Personnel expenses - Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates (Details)", "shortName": "Personnel expenses - Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:ExpectedDividendOtherEquityInstrumentsGranted", "unitRef": "chfPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R87": { "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails", "longName": "9955562 - Disclosure - Personnel expenses - Disclosure of Movements in the Number of All Issues RSUs, PSUs and Share Options (Details)", "shortName": "Personnel expenses - Disclosure of Movements in the Number of All Issues RSUs, PSUs and Share Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-6", "name": "moln:NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R88": { "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails", "longName": "9955563 - Disclosure - Personnel expenses - Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments (Details)", "shortName": "Personnel expenses - Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "moln:WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R89": { "role": "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails", "longName": "9955564 - Disclosure - Personnel expenses - Disclosure of Non-Cash Costs for Share-Based Payments by Functions (Details)", "shortName": "Personnel expenses - Disclosure of Non-Cash Costs for Share-Based Payments by Functions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "moln:DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "moln:DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails", "longName": "9955565 - Disclosure - Financial income and financial expense - Disclosure of Detailed Information about Financial Income (Details)", "shortName": "Financial income and financial expense - Disclosure of Detailed Information about Financial Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails", "longName": "9955566 - Disclosure - Financial income and financial expense - Disclosure of Detailed Information about Financial Expense (Details)", "shortName": "Financial income and financial expense - Disclosure of Detailed Information about Financial Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:NetForeignExchangeLoss", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:NetForeignExchangeLoss", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.molecularpartners.com/role/IncomeTaxesIncomeTaxesDetails", "longName": "9955567 - Disclosure - Income Taxes - Income Taxes (Details)", "shortName": "Income Taxes - Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:ApplicableTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-244", "name": "ifrs-full:CurrentTaxExpenseIncome", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R93": { "role": "http://www.molecularpartners.com/role/IncomeTaxesDeferredTaxesDetails", "longName": "9955568 - Disclosure - Income Taxes - Deferred Taxes (Details)", "shortName": "Income Taxes - Deferred Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-1", "name": "moln:NetOperatingLosses", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:NetOperatingLosses", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails", "longName": "9955569 - Disclosure - Income Taxes - Disclosure of Expiry of Tax Loss Carryforwards (Details)", "shortName": "Income Taxes - Disclosure of Expiry of Tax Loss Carryforwards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-5", "name": "moln:TaxLossCarryforwards", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-247", "name": "moln:TaxLossCarryforwards", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R95": { "role": "http://www.molecularpartners.com/role/EarningspershareDetails", "longName": "9955570 - Disclosure - Earnings per share (Details)", "shortName": "Earnings per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:WeightedAverageShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:EarningsPerShareExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:WeightedAverageShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:EarningsPerShareExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R96": { "role": "http://www.molecularpartners.com/role/LeasesNarrativeDetails", "longName": "9955571 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:CashOutflowForLeases", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-257", "name": "moln:LeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R97": { "role": "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails", "longName": "9955572 - Disclosure - Leases - Disclosure of Movement of Lease Liabilities (Details)", "shortName": "Leases - Disclosure of Movement of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "c-6", "name": "ifrs-full:LeaseLiabilities", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:IncreaseThroughNewLeasesAndLeaseExtensionOperatingLeases", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "moln:DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "unique": true } }, "R98": { "role": "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails", "longName": "9955573 - Disclosure - Leases - Disclosure of Expenses Recognised in Profit or Loss (Details)", "shortName": "Leases - Disclosure of Expenses Recognised in Profit or Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:DepreciationRightofuseAssets", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:DepreciationRightofuseAssets", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R99": { "role": "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails", "longName": "9955574 - Disclosure - Leases - Disclosure of Contractual Maturities of Financial Liabilities (Details)", "shortName": "Leases - Disclosure of Contractual Maturities of Financial Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "c-5", "name": "ifrs-full:GrossLeaseLiabilities", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ifrs-full:GrossLeaseLiabilities", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R100": { "role": "http://www.molecularpartners.com/role/RelatedpartydisclosuresDetails", "longName": "9955575 - Disclosure - Related party disclosures (Details)", "shortName": "Related party disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R101": { "role": "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "longName": "9955576 - Disclosure - Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Exchange Rates (Details)", "shortName": "Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Exchange Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "c-267", "name": "moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-267", "name": "moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R102": { "role": "http://www.molecularpartners.com/role/FinancialriskmanagementAdditionalInformationDetails", "longName": "9955577 - Disclosure - Financial risk management - Additional Information (Details)", "shortName": "Financial risk management - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "c-1", "name": "moln:CashBalancesInvestmentsNumberOfDifferentSwissBanks", "unitRef": "bank", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "moln:CashBalancesInvestmentsNumberOfDifferentSwissBanks", "unitRef": "bank", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R103": { "role": "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails", "longName": "9955578 - Disclosure - Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Interest Rates (Details)", "shortName": "Financial risk management - Sensitivity Analysis to Reasonable Possible Change in Interest Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "c-273", "name": "moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-273", "name": "moln:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R104": { "role": "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails", "longName": "9955579 - Disclosure - Financial risk management - Disclosure of Maximum Credit Risk Exposure (Details)", "shortName": "Financial risk management - Disclosure of Maximum Credit Risk Exposure (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "c-287", "name": "ifrs-full:MaximumExposureToCreditRisk", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfCreditRiskExposureExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-287", "name": "ifrs-full:MaximumExposureToCreditRisk", "unitRef": "chf", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfCreditRiskExposureExplanatory", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } }, "R105": { "role": "http://www.molecularpartners.com/role/RestructuringexpenseDetails", "longName": "9955580 - Disclosure - Restructuring expense (Details)", "shortName": "Restructuring expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "c-289", "name": "moln:RestructuringActivitiesNumberOfPositionsEliminated", "unitRef": "position", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-289", "name": "moln:RestructuringActivitiesNumberOfPositionsEliminated", "unitRef": "position", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "moln-20251231.htm", "first": true, "unique": true } } }, "tag": { "moln_A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "A2021LicenseAndCollaborationAgreementWithNovartisDARPINConjugatedRadioligandTherapiesMember", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licence and Collaboration Agreement with Novartis", "label": "2021 License And Collaboration Agreement With Novartis, DARPIN Conjugated Radioligand Therapies [Member]", "documentation": "2021 License And Collaboration Agreement With Novartis, DARPIN Conjugated Radioligand Therapies" } } }, "auth_ref": [] }, "moln_AccountingEstimatesAndJudgmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AccountingEstimatesAndJudgmentsAbstract", "lang": { "en-us": { "role": { "label": "Accounting Estimates and Judgments [Abstract]", "documentation": "Accounting Estimates and Judgments [Abstract]" } } }, "auth_ref": [] }, "moln_AccruedIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AccruedIncomeMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued income", "label": "Accrued Income [Member]", "documentation": "Accrued Income" } } }, "auth_ref": [] }, "moln_AccruedProjectCostsAndRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AccruedProjectCostsAndRoyaltiesMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued project costs and royalties", "label": "Accrued Project Costs And Royalties [Member]", "documentation": "Accrued Project Costs And Royalties" } } }, "auth_ref": [] }, "moln_AccruedSabbaticalCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AccruedSabbaticalCost", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued sabbatical cost", "label": "Accrued Sabbatical Cost", "documentation": "Accrued Sabbatical Cost" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails", "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation", "label": "Accumulated depreciation and amortisation [member]" } } }, "auth_ref": [ "r9", "r470", "r482", "r483", "r484" ] }, "moln_ActiveMembersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ActiveMembersMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Active members", "label": "Active Members [Member]", "documentation": "Active Members" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Actuarial assumption of discount rates" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r475" ] }, "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRatesMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of discount rates", "label": "Actuarial assumption of discount rates [member]" } }, "en": { "role": { "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r476" ] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future salary increases at December 31", "label": "Actuarial assumption of expected rates of salary increases" } }, "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [domain]; Defined benefit obligation, at present value; Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r475" ] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of expected rates of salary increases", "label": "Actuarial assumption of expected rates of salary increases [member]" } }, "en": { "role": { "documentation": "This member stands for the expected rates of salary increases used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r476" ] }, "moln_ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ActuarialAssumptionOfInterestRateOnRetirementSavingsCapitalMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of interest rate on retirement savings capital", "label": "Actuarial Assumption Of Interest Rate On Retirement Savings Capital [Member]", "documentation": "Actuarial Assumption Of Interest Rate On Retirement Savings Capital" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfLifeExpectancyAfterRetirementMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionOfLifeExpectancyAfterRetirementMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumption of life expectancy", "label": "Actuarial assumption of life expectancy after retirement [member]" } }, "en": { "role": { "documentation": "This member stands for the life expectancy after retirement used as actuarial assumptions. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r476" ] }, "moln_ActuarialAssumptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ActuarialAssumptionsAbstract", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumptions", "label": "Actuarial Assumptions [Abstract]", "documentation": "Actuarial Assumptions" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionsAxis", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumptions [axis]", "label": "Actuarial assumptions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r25" ] }, "ifrs-full_ActuarialAssumptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialAssumptionsDomain", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumptions [domain]", "label": "Actuarial assumptions [domain]" } }, "en": { "role": { "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used." } } }, "auth_ref": [ "r25" ] }, "moln_ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ActuarialAssumptionsPossibleIncreaseDecreaseInLongevityForMostOfTheAgeCategories", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Actuarial assumptions, possible increase (decrease) in longevity for most of the age categories", "label": "Actuarial Assumptions, Possible Increase (Decrease) In Longevity For Most Of The Age Categories", "documentation": "Actuarial Assumptions, Possible Increase (Decrease) In Longevity For Most Of The Age Categories" } } }, "auth_ref": [] }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial (gain) / loss on changes in demographic assumptions", "label": "Actuarial gains (losses) arising from changes in demographic assumptions, net of tax, defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions]" } } }, "auth_ref": [ "r472" ] }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial (gain) / loss on changes in financial assumptions", "label": "Actuarial gains (losses) arising from changes in financial assumptions, net of tax, defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions]" } } }, "auth_ref": [ "r472" ] }, "ifrs-full_ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ActuarialGainsLossesArisingFromExperienceAdjustmentsNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Actuarial (gain) / loss arising from experience adjustments", "label": "Actuarial gains (losses) arising from experience adjustments, net of tax, defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from experience adjustments that result in remeasurements of the net defined benefit liability (asset). Experience adjustments deal with the effects of differences between the previous actuarial assumptions and what has actually occurred. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from experience adjustments]" } } }, "auth_ref": [ "r472" ] }, "moln_ActuarialGainsLossesNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ActuarialGainsLossesNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Actuarial (gain)/loss on defined benefit obligation", "label": "Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans", "documentation": "Actuarial Gains (Losses), Net Of Tax, Defined Benefit Plans" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r405" ] }, "ifrs-full_AdditionalPaidinCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionalPaidinCapital", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional paid-in capital" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r500" ] }, "ifrs-full_AdditionalPaidinCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionalPaidinCapitalMember", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional paid-in capital [member]" } }, "en": { "role": { "documentation": "This member stands for amounts received from issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r495" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r47", "r217" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Additions other than through business combinations, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment including right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r471" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AddressTypeDomain", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r418" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r418" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r418" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r418" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.molecularpartners.com/role/EarningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing diluted earnings per share (in shares)", "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r41" ] }, "moln_AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AdjustmentForExchangeGainsLossesOnWorkingCapitalPositions", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exchange (loss) gain on working capital positions", "label": "Adjustment For Exchange Gains (Losses) On Working Capital Positions", "documentation": "Adjustment For Exchange Gains (Losses) On Working Capital Positions" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in other current assets", "label": "Adjustments for decrease (increase) in other current assets" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]" } } }, "auth_ref": [ "r489" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in trade and other receivables", "label": "Adjustments for decrease (increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r489" ] }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Adjustments for depreciation and amortisation expense" } } }, "auth_ref": [ "r487" ] }, "ifrs-full_AdjustmentsForFinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceCosts", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Financial expenses", "label": "Adjustments for finance costs" } } }, "auth_ref": [ "r488" ] }, "ifrs-full_AdjustmentsForFinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFinanceIncome", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial income", "label": "Adjustments for finance income" } } }, "auth_ref": [ "r489" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax", "label": "Adjustments for income tax expense" } } }, "auth_ref": [ "r64" ] }, "moln_AdjustmentsForIncreaseDecreaseInAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AdjustmentsForIncreaseDecreaseInAccruedExpenses", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in accrued expenses", "label": "Adjustments For Increase (Decrease) In Accrued Expenses", "documentation": "Adjustments For Increase (Decrease) In Accrued Expenses" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInContractLiabilities", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in contract liability", "label": "Adjustments for increase (decrease) in contract liabilities" } }, "en": { "role": { "documentation": "Adjustments for the increase (decrease) in contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Contract liabilities; Profit (loss)]" } } }, "auth_ref": [ "r486" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in employee benefits", "label": "Adjustments for increase (decrease) in employee benefit liabilities" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r489" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in trade and other payables", "label": "Adjustments for increase (decrease) in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r489" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments for:", "label": "Adjustments to reconcile profit (loss) [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation costs", "label": "Adjustments for share-based payments" } } }, "auth_ref": [ "r487" ] }, "moln_AdjustmentsForSocialSecurityAndTaxPaidOnEmployeeSharesVested": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AdjustmentsForSocialSecurityAndTaxPaidOnEmployeeSharesVested", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Social security and tax paid on behalf of employees on shares vested under the PSU and RSU program", "label": "Adjustments For Social Security And Tax Paid On Employee Shares Vested", "documentation": "Adjustments For Social Security And Tax Paid On Employee Shares Vested" } } }, "auth_ref": [] }, "ifrs-full_AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdministrationCostsNotReflectedInReturnOnPlanAssetsDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Administrative cost excl. cost for managing plan assets", "label": "Administration costs not reflected in return on plan assets, defined benefit plans" } } }, "auth_ref": [ "r472" ] }, "ifrs-full_AdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdministrativeExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": "ifrs-full_SellingGeneralAndAdministrativeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other administrative expenses", "label": "Administrative expenses" } } }, "auth_ref": [ "r36", "r296", "r348" ] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r463" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r376", "r387", "r397", "r430" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r379", "r390", "r400", "r433" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r464" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r418" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails", "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsNarrativeDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails", "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails", "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r425" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r380", "r391", "r401", "r425", "r434", "r438", "r446" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r444" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "moln_AmericanDepositorySharesTheNasdaqStockMarketLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AmericanDepositorySharesTheNasdaqStockMarketLLCMember", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "American depositary shares (each representing one ordinary share, CHF 0.10 nominal value per share)", "label": "American Depository Shares, The Nasdaq Stock Market LLC [Member]", "documentation": "American Depository Shares, The Nasdaq Stock Market LLC" } } }, "auth_ref": [] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization charge for the year", "label": "Amortisation, intangible assets other than goodwill" } } }, "auth_ref": [ "r49", "r219" ] }, "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AnalysisOfIncomeAndExpenseAbstract", "lang": { "en-us": { "role": { "label": "Analysis of income and expense [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable tax rate", "label": "Applicable tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r3", "r192" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r83", "r84", "r85", "r156", "r158", "r251", "r252", "r276" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [abstract]" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails", "http://www.molecularpartners.com/role/RestructuringexpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [axis]", "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r493", "r496" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails", "http://www.molecularpartners.com/role/RestructuringexpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Attribution of expenses by nature to their function [domain]", "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r493", "r496" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorFirmId", "presentation": [ "http://www.molecularpartners.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r359", "r360", "r383" ] }, "moln_AuditorInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AuditorInformationAbstract", "lang": { "en-us": { "role": { "label": "Auditor Information [Abstract]", "documentation": "Auditor Information" } } }, "auth_ref": [] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorLocation", "presentation": [ "http://www.molecularpartners.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r359", "r360", "r383" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditorName", "presentation": [ "http://www.molecularpartners.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r359", "r360", "r383" ] }, "moln_AuthorizedShareCapitalEmployeeParticipation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AuthorizedShareCapitalEmployeeParticipation", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized share capital, employee participation", "label": "Authorized Share Capital, Employee Participation", "documentation": "Authorized Share Capital, Employee Participation" } } }, "auth_ref": [] }, "moln_AuthorizedShareCapitalFinancingTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AuthorizedShareCapitalFinancingTransactions", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized share capital, financing transactions", "label": "Authorized Share Capital, Financing Transactions", "documentation": "Authorized Share Capital, Financing Transactions" } } }, "auth_ref": [] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageEffectiveTaxRate", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average effective tax rate", "label": "Average effective tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r192" ] }, "moln_AverageNumberOfFullTimeEquivalentEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AverageNumberOfFullTimeEquivalentEmployees", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average number of full-time equivalents", "label": "Average Number Of Full-Time Equivalent Employees", "documentation": "Average Number Of Full-Time Equivalent Employees" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r441" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r442" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r437" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r437" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r437" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r437" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r437" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r437" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r440" ] }, "moln_AwardVestingPercentageOfShareBasedPaymentArrangement": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "AwardVestingPercentageOfShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award vesting percentage", "label": "Award Vesting Percentage Of Share-Based Payment Arrangement", "documentation": "Award Vesting Percentage Of Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r439" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r438" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r438" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "terseLabel": "Basic net result per share (in CHF per share)", "label": "Basic earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r39", "r40" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "BusinessContactMember", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Business Contact", "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r360", "r383" ] }, "country_CH": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "CH", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyCountryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues Switzerland", "label": "SWITZERLAND" } } }, "auth_ref": [] }, "currency_CHF": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "CHF", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails", "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsNarrativeDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails", "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CHF", "verboseLabel": "CHF Positions", "label": "Switzerland, Francs" } } }, "auth_ref": [] }, "ifrs-full_CapitalCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CapitalCommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Capital commitments [abstract]" } } }, "auth_ref": [] }, "moln_CapitalRangeLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "CapitalRangeLimit", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital range limit", "label": "Capital Range Limit", "documentation": "Capital Range Limit" } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails", "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6", "r7", "r46", "r50", "r54", "r55", "r56", "r57", "r58", "r126", "r136", "r137", "r194", "r195", "r216", "r220", "r223", "r224", "r225", "r226", "r227", "r239", "r247", "r248" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails", "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying amount [member]", "label": "Carrying amount [member]" } } }, "auth_ref": [ "r7", "r50", "r54", "r56", "r57", "r126", "r136", "r137", "r195", "r220", "r223", "r225", "r226", "r239", "r247", "r248" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails", "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows", "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at January 1", "periodEndLabel": "Cash and cash equivalents at December 31", "label": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r66", "r80", "r185", "r274" ] }, "moln_CashAndCashEquivalents1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "CashAndCashEquivalents1Member", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash And Cash Equivalents 1 [Member]", "documentation": "Cash And Cash Equivalents 1" } } }, "auth_ref": [] }, "ifrs-full_CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsAmountContributedToFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_PlanAssetsAtFairValue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and cash equivalents, amount contributed to fair value of plan assets" } }, "en": { "role": { "documentation": "The amount cash and cash equivalents contribute to the fair value of defined benefit plan assets. [Refer: Cash and cash equivalents; Plan assets, at fair value; Defined benefit plans [domain]]" } } }, "auth_ref": [ "r301" ] }, "moln_CashBalancesInvestmentsNumberOfDifferentSwissBanks": { "xbrltype": "integerItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "CashBalancesInvestmentsNumberOfDifferentSwissBanks", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of different Swiss banks", "label": "Cash Balances Investments, Number Of Different Swiss Banks", "documentation": "Cash Balances Investments, Number Of Different Swiss Banks" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash from (used in) financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r59", "r68" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash from (used in) investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r59", "r68" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) from operating activities", "label": "Cash flows from (used in) operating activities" } } }, "auth_ref": [ "r59", "r68" ] }, "ifrs-full_CashOutflowForLeases": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashOutflowForLeases", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails", "http://www.molecularpartners.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash outflow for leases", "negatedLabel": "Payments", "label": "Cash outflow for leases" } }, "en": { "role": { "documentation": "The cash outflow for leases." } } }, "auth_ref": [ "r98", "r169" ] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [axis]", "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r150", "r243" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial assets [domain]", "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r150", "r243" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities [axis]", "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r150", "r243" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Categories of financial liabilities [domain]", "label": "Categories of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r150", "r243" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r416" ] }, "ifrs-full_ChangesInNetDefinedBenefitLiabilityAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ChangesInNetDefinedBenefitLiabilityAssetAbstract", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of net defined benefit liability", "label": "Changes in net defined benefit liability (asset) [abstract]" } } }, "auth_ref": [] }, "moln_ChangesInWorkingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ChangesInWorkingCapitalAbstract", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in working capital:", "label": "Changes In Working Capital [Abstract]", "documentation": "Changes In Working Capital" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r413" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r411" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [axis]", "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r114", "r145", "r146", "r162", "r163", "r261" ] }, "ifrs-full_ClassesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsDomain", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial assets [domain]", "label": "Classes of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r114", "r145", "r146", "r162", "r163", "r261" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [axis]", "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r136", "r139", "r141", "r142", "r247", "r250" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial instruments [domain]", "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r136", "r139", "r141", "r142", "r247", "r250" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [axis]", "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r145", "r146", "r162", "r163" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of financial liabilities [domain]", "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r145", "r146", "r162", "r163" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [axis]", "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r51", "r221" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillDomain", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of intangible assets other than goodwill [domain]", "label": "Classes of intangible assets other than goodwill [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used." } } }, "auth_ref": [ "r51", "r221" ] }, "ifrs-full_ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPlanAssetsFairValueMonetaryAmountsAbstract", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan asset classes", "label": "Classes of plan assets, fair value monetary amounts [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [axis]", "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r8", "r196" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of property, plant and equipment [domain]", "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r8", "r196" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.molecularpartners.com/role/Cover", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [axis]", "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r182", "r255", "r287" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://www.molecularpartners.com/role/Cover", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Classes of share capital [domain]", "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r182", "r255", "r287" ] }, "moln_CoDevelopmentAgreementWithOranoMedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "CoDevelopmentAgreementWithOranoMedMember", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Co-development Agreement with Orano Med", "label": "Co-Development Agreement With Orano Med [Member]", "documentation": "Co-development Agreement with Orano Med" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r417" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r417" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r422" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r421" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r423" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r420" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [axis]", "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r268" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of equity [domain]", "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r268" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "terseLabel": "Items that are or may be reclassified subsequently to profit or loss", "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "terseLabel": "Items that will not be reclassified to profit or loss", "label": "Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive result, attributable to shareholders", "label": "Comprehensive income" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r71", "r73", "r78", "r213", "r229", "r263", "r291", "r314" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IT hardware", "label": "Computer equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r469" ] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Computer software [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r308" ] }, "moln_ConditionalShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ConditionalShareCapitalMember", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conditional share capital", "label": "Conditional Share Capital [Member]", "documentation": "Conditional Share Capital" } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "ContactPersonnelName", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Contact Personnel Name", "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "ifrs-full_ContractLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Contract liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Contributions by the employer", "terseLabel": "Contributions by the employer", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from resulting from contributions to plan by employer" } }, "en": { "role": { "documentation": "The decrease (increase) in net defined benefit liability (asset) resulting from contributions to a defined benefit plan by the employer. [Refer: Net defined benefit liability (asset); Defined benefit plans [domain]]" } } }, "auth_ref": [ "r20" ] }, "ifrs-full_ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContributionsToPlanByPlanParticipantsNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Contributions by plan participants", "terseLabel": "Contributions by plan participants", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from contributions to plan by plan participants" } }, "en": { "role": { "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from contributions to a defined benefit plan by plan participants. [Refer: Net defined benefit liability (asset); Defined benefit plans [domain]]" } } }, "auth_ref": [ "r20" ] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.molecularpartners.com/role/ContractliabilityDetails", "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [axis]", "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r151" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://www.molecularpartners.com/role/ContractliabilityDetails", "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparties [domain]", "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r151" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Country Region", "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "ifrs-full_CreditRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CreditRiskMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit risk", "label": "Credit risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r108", "r109", "r110", "r326" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails", "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsNarrativeDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails", "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails", "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency risk", "label": "Currency risk [member]" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r108", "r109", "r110", "r111", "r152" ] }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.molecularpartners.com/role/AccruedexpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/AccruedexpensesDetails", "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses", "label": "Current accrued expenses and other current liabilities" } }, "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } } }, "auth_ref": [ "r500" ] }, "ifrs-full_CurrentAccruedIncomeOtherThanCurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAccruedIncomeOtherThanCurrentContractAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/OthercurrentassetsDetails": { "parentTag": "ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/OthercurrentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued income", "label": "Current accrued income other than current contract assets" } }, "en": { "role": { "documentation": "The amount of current accrued income other than current contract assets. [Refer: Accrued income other than contract assets]" } } }, "auth_ref": [ "r500", "r502" ] }, "moln_CurrentAccruedProjectCostsAndRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "CurrentAccruedProjectCostsAndRoyalties", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/AccruedexpensesDetails": { "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AccruedexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued project costs and royalties", "label": "Current Accrued Project Costs And Royalties", "documentation": "Current Accrued Project Costs And Royalties" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r74", "r279", "r314" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails": { "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0, "order": 2.0 }, "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition", "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "verboseLabel": "Current", "label": "Current lease liabilities" } }, "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r95" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r76", "r280", "r314" ] }, "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Social security", "label": "Current payables on social security and taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } } }, "auth_ref": [ "r502" ] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/OthercurrentassetsDetails": { "parentTag": "ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/OthercurrentassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayments", "label": "Current prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r496" ] }, "ifrs-full_CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaymentsAndCurrentAccruedIncomeOtherThanCurrentContractAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/OthercurrentassetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/OthercurrentassetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Balance at December 31", "label": "Current prepayments and current accrued income other than current contract assets" } }, "en": { "role": { "documentation": "The amount of current prepayments and current accrued income, other than current contract assets. [Refer: Prepayments; Accrued income other than contract assets]" } } }, "auth_ref": [ "r500", "r502" ] }, "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Withholding tax", "label": "Current receivables from taxes other than income tax" } }, "en": { "role": { "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]" } } }, "auth_ref": [ "r501" ] }, "ifrs-full_CurrentServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current service cost (employer)", "label": "Current service cost, defined benefit plans" } } }, "auth_ref": [ "r472" ] }, "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current service cost (employer)", "label": "Increase in net defined benefit liability (asset) resulting from current service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r15", "r201" ] }, "ifrs-full_CurrentTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncome", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current tax expense (income)", "label": "Current tax expense (income)" } } }, "auth_ref": [ "r298", "r339" ] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails", "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r345", "r350", "r352" ] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value added tax", "label": "Current value added tax receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r501" ] }, "moln_CurtailmentGainLossDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "CurtailmentGainLossDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Curtailment", "label": "Curtailment Gain (Loss), Defined Benefit Plans", "documentation": "Curtailment Gain (Loss), Defined Benefit Plans" } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r368", "r457" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r368", "r457" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r370", "r459" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r370", "r459" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r372", "r461" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r370", "r459" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r363", "r452" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r364", "r453" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r364", "r453" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r362", "r451" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r362", "r451" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r362", "r451" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r365", "r454" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r367", "r456" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r367", "r456" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r368", "r457" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r371", "r460" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r369", "r458" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2025", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r366", "r455" ] }, "ifrs-full_DebtInstrumentsAmountContributedToFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DebtInstrumentsAmountContributedToFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_PlanAssetsAtFairValue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instruments (e.g. bonds)", "label": "Debt instruments, amount contributed to fair value of plan assets" } }, "en": { "role": { "documentation": "The amount instruments representing debt (rather than equity) contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [domain]]" } } }, "auth_ref": [ "r303", "r341" ] }, "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/ContractliabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease through performance obligation being satisfied, contract liabilities", "label": "Decrease through performance obligation being satisfied, contract liabilities" } }, "en": { "role": { "documentation": "The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [domain]]" } } }, "auth_ref": [ "r317" ] }, "ifrs-full_DefinedBenefitObligationAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitObligationAtPresentValue", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_LiabilityAssetOfDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit obligation at December 31", "label": "Defined benefit obligation, at present value" } }, "en": { "role": { "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]" } } }, "auth_ref": [ "r478" ] }, "moln_DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit obligation due to reasonably possible decrease in actuarial assumption", "label": "Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption", "documentation": "Defined Benefit Obligation Due To Reasonably Possible Decrease In Actuarial Assumption" } } }, "auth_ref": [] }, "moln_DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit obligation due to reasonably possible increase in actuarial assumption", "label": "Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption", "documentation": "Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption" } } }, "auth_ref": [] }, "moln_DefinedBenefitPlanEmployeeContribution": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DefinedBenefitPlanEmployeeContribution", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit plan, employee contribution", "label": "Defined Benefit Plan, Employee Contribution", "documentation": "Defined Benefit Plan, Employee Contribution" } } }, "auth_ref": [] }, "moln_DefinedBenefitPlanEmployerContribution": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DefinedBenefitPlanEmployerContribution", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit plan, employer contribution", "label": "Defined Benefit Plan, Employer Contribution", "documentation": "Defined Benefit Plan, Employer Contribution" } } }, "auth_ref": [] }, "moln_DefinedBenefitPlanNumberOfEligibleEmployees": { "xbrltype": "integerItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DefinedBenefitPlanNumberOfEligibleEmployees", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of eligible employees", "label": "Defined Benefit Plan, Number Of Eligible Employees", "documentation": "Defined Benefit Plan, Number Of Eligible Employees" } } }, "auth_ref": [] }, "moln_DefinedBenefitPlanNumberOfEmployeesThatParticipated": { "xbrltype": "integerItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DefinedBenefitPlanNumberOfEmployeesThatParticipated", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees that participated", "label": "Defined Benefit Plan, Number Of Employees That Participated", "documentation": "Defined Benefit Plan, Number Of Employees That Participated" } } }, "auth_ref": [] }, "ifrs-full_DefinedBenefitPlansAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitPlansAxis", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit plans [axis]", "label": "Defined benefit plans [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r11", "r197" ] }, "ifrs-full_DefinedBenefitPlansDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitPlansDomain", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit plans [domain]", "label": "Defined benefit plans [domain]" } }, "en": { "role": { "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used." } } }, "auth_ref": [ "r11", "r197" ] }, "ifrs-full_DepreciationAndAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationAndAmortisationExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation and amortization", "label": "Depreciation and amortisation expense" } }, "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } } }, "auth_ref": [ "r81", "r154", "r160", "r262", "r296", "r347" ] }, "ifrs-full_DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipmentIncludingRightofuseAssets", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation charge for the year", "label": "Depreciation, property, plant and equipment including right-of-use assets" } } }, "auth_ref": [ "r471" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "calculation": { "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails": { "parentTag": "moln_LeaseCostRecognisedInProfitOrLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation on right-of-use assets", "label": "Depreciation, right-of-use assets" } } }, "auth_ref": [ "r96", "r167" ] }, "moln_DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DescriptionOfAccountingPolicyForBasisOfConsolidationPolicyPolicyTextBlock", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of consolidation", "label": "Description Of Accounting Policy For Basis Of Consolidation Policy [Policy Text Block]", "documentation": "Description Of Accounting Policy For Basis Of Consolidation Policy" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits", "label": "Description of accounting policy for employee benefits [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets at amortized costs", "label": "Description of accounting policy for financial assets [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities at amortized costs", "label": "Description of accounting policy for financial liabilities [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation / transactions", "label": "Description of accounting policy for foreign currency translation [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Description of accounting policy for income tax [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Description of accounting policy for intangible assets other than goodwill [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital / Additional paid-in capital", "label": "Description of accounting policy for issued capital [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Description of accounting policy for property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognition", "label": "Description of accounting policy for recognition of revenue [text block]" } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Description of accounting policy for research and development expense [text block]" } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment reporting", "label": "Description of accounting policy for segment reporting [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r497" ] }, "moln_DescriptionOfAccountingPolicyForShortTermDepositsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DescriptionOfAccountingPolicyForShortTermDepositsTextBlock", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term time deposits", "label": "Description Of Accounting Policy For Short Term Deposits [Text Block]", "documentation": "Description Of Accounting Policy For Short Term Deposits" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForTreasurySharesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForTreasurySharesExplanatory", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares", "label": "Description of accounting policy for treasury shares [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for treasury shares. [Refer: Treasury shares]" } } }, "auth_ref": [ "r497" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r67", "r186" ] }, "ifrs-full_DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAmountsOfEntitysOwnFinancialInstrumentsIncludedInFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof entity's own transferable financial instruments", "label": "Entity's own financial instruments included in fair value of plan assets" } }, "en": { "role": { "documentation": "The fair value of the entity's own transferable financial instruments that are included in the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Classes of financial instruments [domain]; Defined benefit plans [domain]]" } } }, "auth_ref": [ "r23", "r207" ] }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New or revised IFRS standards and interpretations", "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]" } } }, "auth_ref": [ "r69", "r188" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted net result per share (in CHF per share)", "label": "Diluted earnings (loss) per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r39", "r40" ] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Accountingestimatesandjudgments" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting estimates and judgments", "label": "Disclosure of accounting judgements and estimates [text block]" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r492" ] }, "ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Accruedexpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Disclosure of accrued expenses and other liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]" } } }, "auth_ref": [ "r492" ] }, "ifrs-full_DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAdditionalInformationAboutLeasingActivitiesForLesseeExplanatory", "presentation": [ "http://www.molecularpartners.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Expenses Recognised in Profit or Loss", "label": "Disclosure of additional information about leasing activities for lessee [text block]" } }, "en": { "role": { "documentation": "The disclosure of additional information about leasing activities of a lessee." } } }, "auth_ref": [ "r100", "r171" ] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionExplanatory", "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Attribution of Expenses by Nature", "label": "Disclosure of attribution of expenses by nature to their function [text block]" } } }, "auth_ref": [ "r493", "r496" ] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails", "http://www.molecularpartners.com/role/RestructuringexpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of attribution of expenses by nature to their function [line items]", "label": "Disclosure of attribution of expenses by nature to their function [line items]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails", "http://www.molecularpartners.com/role/RestructuringexpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of attribution of expenses by nature to their function [table]", "label": "Disclosure of attribution of expenses by nature to their function [table]" } } }, "auth_ref": [ "r493", "r496" ] }, "moln_DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfCashCashEquivalentsAndShortTermTimeDepositsTextBlock", "presentation": [ "http://www.molecularpartners.com/role/Cashandcashequivalentsandshorttermtimedeposits" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents and short-term time deposits", "label": "Disclosure Of Cash, Cash Equivalents And Short-Term Time Deposits [Text Block]", "documentation": "Disclosure Of Cash, Cash Equivalents And Short-Term Time Deposits" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of issuance of shares", "label": "Disclosure of classes of share capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r182", "r255", "r287" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [line items]", "label": "Disclosure of classes of share capital [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of classes of share capital [table]", "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r182", "r255", "r287" ] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Capitalcommitments" ], "lang": { "en-us": { "role": { "terseLabel": "Capital commitments", "label": "Disclosure of commitments [text block]" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r492" ] }, "ifrs-full_DisclosureOfCreditRiskExposureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCreditRiskExposureExplanatory", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Maximum Credit Risk Exposure", "label": "Disclosure of credit risk exposure [text block]" } }, "en": { "role": { "documentation": "The disclosure of the credit risk exposure. Credit risk exposure is the credit risk inherent in an entity\u2019s financial assets and commitments to extend credit." } } }, "auth_ref": [ "r141", "r250" ] }, "ifrs-full_DisclosureOfCreditRiskExposureLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCreditRiskExposureLineItems", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of credit risk exposure [line items]", "label": "Disclosure of credit risk exposure [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCreditRiskExposureTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCreditRiskExposureTable", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of credit risk exposure [table]", "label": "Disclosure of credit risk exposure [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the credit risk exposure." } } }, "auth_ref": [ "r141", "r250" ] }, "moln_DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfCurrentAccruedExpensesAndOtherCurrentLiabilitiesExplanatoryTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/AccruedexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Accrued Expenses Explanatory", "label": "Disclosure Of Current Accrued Expenses And Other Current Liabilities Explanatory [Table Text Block]", "documentation": "Disclosure Of Current Accrued Expenses And Other Current Liabilities Explanatory" } } }, "auth_ref": [] }, "moln_DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDefinedBenefitPlanExpenseRecognizedInProfitOrLossAndOtherComprehensiveIncomeExplanatoryTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Defined Benefit Plan, Expense Recognized in Profit or Loss and Other Comprehensive Income", "label": "Disclosure Of Defined Benefit Plan, Expense Recognized In Profit Or Loss And Other Comprehensive Income Explanatory [Table Text Block]", "documentation": "Disclosure Of Defined Benefit Plan, Expense Recognized In Profit Or Loss And Other Comprehensive Income Explanatory" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsLineItems", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]", "label": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]", "documentation": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutCashCashEquivalentsAndShortTermTimeDepositsTable", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Table]", "label": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits [Table]", "documentation": "Disclosure Of Detailed Information About Cash, Cash Equivalents And Short-Term Time Deposits" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutContractLiabilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutContractLiabilityLineItems", "presentation": [ "http://www.molecularpartners.com/role/ContractliabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Contract Liability [Line Items]", "label": "Disclosure Of Detailed Information About Contract Liability [Line Items]", "documentation": "Disclosure Of Detailed Information About Contract Liability" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutContractLiabilityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutContractLiabilityTable", "presentation": [ "http://www.molecularpartners.com/role/ContractliabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Contract Liability [Table]", "label": "Disclosure Of Detailed Information About Contract Liability [Table]", "documentation": "Disclosure Of Detailed Information About Contract Liability" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsLineItems", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Employee Benefits [Line Items]", "label": "Disclosure Of Detailed Information About Employee Benefits [Line Items]", "documentation": "Disclosure Of Detailed Information About Employee Benefits [Line Items]" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutEmployeeBenefitsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutEmployeeBenefitsTable", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Employee Benefits [Table]", "label": "Disclosure Of Detailed Information About Employee Benefits [Table]", "documentation": "Disclosure Of Detailed Information About Employee Benefits [Table]" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutEmployeeExpensesAndHeadCountTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Detailed Information about Employee Expenses and Head Count", "label": "Disclosure Of Detailed Information About Employee Expenses And Head Count [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Employee Expenses And Head Count" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutFinancialExpenseTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Detailed Information about Financial Expense", "label": "Disclosure Of Detailed Information About Financial Expense [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Financial Expense" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutFinancialIncomeTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Detailed Information about Financial Income", "label": "Disclosure Of Detailed Information About Financial Income [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Financial Income" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesLineItems", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails", "http://www.molecularpartners.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]", "label": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Line Items]", "documentation": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutIncomeTaxesAndDeferredTaxesTable", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails", "http://www.molecularpartners.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Table]", "label": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes [Table]", "documentation": "Disclosure Of Detailed Information About Income Taxes And Deferred Taxes" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Reconciliation of Changes in Intangible Assets", "label": "Disclosure of detailed information about intangible assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r51", "r221" ] }, "moln_DisclosureOfDetailedInformationAboutLeasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutLeasesLineItems", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Leases [Line Items]", "label": "Disclosure Of Detailed Information About Leases [Line Items]", "documentation": "Disclosure Of Detailed Information About Leases [Line Items]" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutLeasesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutLeasesTable", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Leases [Table]", "label": "Disclosure Of Detailed Information About Leases [Table]", "documentation": "Disclosure Of Detailed Information About Leases [Table]" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesAndAccruedIncomeTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/OthercurrentassetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Other Current Assets", "label": "Disclosure Of Detailed Information About Prepaid Expenses And Accrued Income [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Prepaid Expenses And Accrued Income" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentTables", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Disclosure of Detailed Information about Property, Plant and Equipment", "terseLabel": "Disclosure of Reconciliation of Changes in Property, Plant and Equipment", "label": "Disclosure of detailed information about property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r8", "r196" ] }, "moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesLineItems", "presentation": [ "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Royalties And License Fees [Line Items]", "label": "Disclosure Of Detailed Information About Royalties And License Fees [Line Items]", "documentation": "Disclosure Of Detailed Information About Royalties And License Fees" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutRoyaltiesAndLicenseFeesTable", "presentation": [ "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Detailed Information About Royalties And License Fees [Table Text Block]", "label": "Disclosure Of Detailed Information About Royalties And License Fees [Table]", "documentation": "Disclosure Of Detailed Information About Royalties And License Fees" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/TradeandotherpayablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Detailed Information about Trade and Other Payables", "label": "Disclosure Of Detailed Information About Trade And Other Payables [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Trade And Other Payables" } } }, "auth_ref": [] }, "moln_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/TradeandotherreceivablesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Detailed Information about Trade and Other Receivables", "label": "Disclosure Of Detailed Information About Trade And Other Receivables [Table Text Block]", "documentation": "Disclosure Of Detailed Information About Trade And Other Receivables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Disaggregation of Revenue from Contracts with Customers", "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]" } } }, "auth_ref": [ "r89", "r165" ] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyCountryDetails", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [line items]", "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyCountryDetails", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of disaggregation of revenue from contracts with customers [table]", "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r89", "r165" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Earningspershare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share", "label": "Disclosure of earnings per share [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r42" ] }, "moln_DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfEmployeeBenefitsAndShareBasedPaymentsArrangementsTextBlock", "presentation": [ "http://www.molecularpartners.com/role/Personnelexpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Personnel expenses", "label": "Disclosure Of Employee Benefits And Share-Based Payments Arrangements [Text Block]", "documentation": "Disclosure Of Employee Benefits And Share-Based Payments Arrangements" } } }, "auth_ref": [] }, "moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsLineItems", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]", "label": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Line Items]", "documentation": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments" } } }, "auth_ref": [] }, "moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTable", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Table]", "label": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Table]", "documentation": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments" } } }, "auth_ref": [] }, "moln_DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfExercisePricesNumberAndWeightedAverageRemainingContractualLifeOfOutstandingInstrumentsTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Exercise Prices, Number and Weighted Average Remaining Contractual Life of Outstanding Instruments", "label": "Disclosure Of Exercise Prices, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments [Table Text Block]", "documentation": "Disclosure Of Exercise Price, Number And Weighted Average Remaining Contractual Life Of Outstanding Instruments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesByNatureExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Additionalinformationonthenatureofexpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Additional information on the nature of expenses", "label": "Disclosure of expenses by nature [text block]" } } }, "auth_ref": [ "r492" ] }, "moln_DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfExpiryOfTaxLossCarryforwardsTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Expiry of Tax Loss Carryforwards", "label": "Disclosure Of Expiry Of Tax Loss Carryforwards [Table Text Block]", "documentation": "Disclosure Of Expiry Of Tax Loss Carryforwards" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Financialincomeandfinancialexpense" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income and financial expense", "label": "Disclosure of finance income (cost) [text block]" } } }, "auth_ref": [ "r492" ] }, "ifrs-full_DisclosureOfFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialAssetsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Financial Assets at Amortized Cost", "label": "Disclosure of financial assets [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r147", "r240" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Financialinstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments", "label": "Disclosure of financial instruments [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r153" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails", "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [line items]", "label": "Disclosure of detailed information about financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails", "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about financial instruments [table]", "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r132", "r139", "r147", "r240" ] }, "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialLiabilitiesExplanatory", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Financial Liabilities at Amortized Cost", "label": "Disclosure of financial liabilities [text block]" } }, "en": { "role": { "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r147", "r240" ] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Financialriskmanagement", "http://www.molecularpartners.com/role/Financialriskmanagement_1" ], "lang": { "en-us": { "role": { "terseLabel": "Financial risk management", "label": "Disclosure of financial risk management [text block]" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r492" ] }, "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Generalinformation" ], "lang": { "en-us": { "role": { "terseLabel": "General information", "label": "Disclosure of general information about financial statements [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for general information about financial statements." } } }, "auth_ref": [ "r178", "r271" ] }, "moln_DisclosureOfGeneralInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfGeneralInformationAbstract", "lang": { "en-us": { "role": { "label": "Disclosure Of General Information [Abstract]", "documentation": "Disclosure Of General Information [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r4" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Conditions and Inputs Used in the Measurement of the Fair Values at Grant Dates", "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r124" ] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Intangibleassets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Disclosure of intangible assets [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r53" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [line items]", "label": "Disclosure of detailed information about intangible assets [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about intangible assets [table]", "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r51", "r221" ] }, "ifrs-full_DisclosureOfLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfLeasesExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Disclosure of leases [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for leases." } } }, "auth_ref": [ "r103", "r104" ] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Summaryofmaterialaccountingpolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of material accounting policies", "label": "Disclosure of material accounting policy information [text block]" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r187", "r257", "r269" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Contractual Maturities of Financial Liabilities", "label": "Disclosure of maturity analysis of operating lease payments [text block]" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } } }, "auth_ref": [ "r102", "r177" ] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems", "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of maturity analysis of operating lease payments [line items]", "label": "Disclosure of maturity analysis of operating lease payments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable", "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Disclosure of maturity analysis of operating lease payments [table]", "label": "Disclosure of maturity analysis of operating lease payments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments." } } }, "auth_ref": [ "r102", "r177" ] }, "moln_DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfMovementOfLeaseLiabilitiesTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Movement of Lease Liabilities", "label": "Disclosure Of Movement Of Lease Liabilities [Table Text Block]", "documentation": "Disclosure Of Movement Of Lease Liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [line items]", "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [table]", "label": "Disclosure of nature and extent of risks arising from financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments." } } }, "auth_ref": [ "r133", "r134" ] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Net Defined Benefit Liability (Asset)", "label": "Disclosure of net defined benefit liability (asset) [text block]" } }, "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r14", "r200" ] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetLineItems", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit pension plans", "label": "Disclosure of net defined benefit liability (asset) [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetTable", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of net defined benefit liability (asset) [table]", "label": "Disclosure of net defined benefit liability (asset) [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the net defined benefit liability (asset)." } } }, "auth_ref": [ "r14", "r200" ] }, "moln_DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfNonCashCostsForShareBasedPaymentsByFunctionsTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Non-Cash Costs for Share-Based Payments by Functions", "label": "Disclosure Of Non-Cash Costs For Share-Based Payments By Functions [Table Text Block]", "documentation": "Disclosure Of Non-Cash Costs For Share-Based Payments By Functions" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Eventsafterthebalancesheetdate" ], "lang": { "en-us": { "role": { "terseLabel": "Events after the balance sheet date", "label": "Disclosure of non-adjusting events after reporting period [text block]" } }, "en": { "role": { "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [domain]]" } } }, "auth_ref": [ "r0", "r189" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Movements in the Number of PSUs and RSUs", "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r490" ] }, "moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsLineItems", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]", "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]", "documentation": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Line Items]" } } }, "auth_ref": [] }, "moln_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsTable", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Table]", "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Table]", "documentation": "Disclosure Of Number And Weighted Average Exercise Prices Of Other Equity Instruments [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Movements in the Number of Share Options", "label": "Disclosure of number and weighted average exercise prices of share options [text block]" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r121", "r236" ] }, "moln_DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfPrepaidExpensesAndAccruedIncomeTextBlock", "presentation": [ "http://www.molecularpartners.com/role/Othercurrentassets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Disclosure Of Prepaid Expenses And Accrued Income [Text Block]", "documentation": "Disclosure Of Prepaid Expenses And Accrued Income" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Propertyplantandequipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Disclosure of property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r10" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]", "label": "Disclosure of detailed information about property, plant and equipment [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]", "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r8", "r196" ] }, "moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsLineItems", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]", "label": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Line Items]", "documentation": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits" } } }, "auth_ref": [] }, "moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTable", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Table]", "label": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Table]", "documentation": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits" } } }, "auth_ref": [] }, "moln_DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfReconciliationOfCashCashEquivalentsAndShortTermTimeDepositsTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Reconciliation of Cash, Cash Equivalents and Short-Term Time Deposits", "label": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits [Table Text Block]", "documentation": "Disclosure Of Reconciliation Of Cash, Cash Equivalents And Short-Term Time Deposits" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Relatedpartydisclosures" ], "lang": { "en-us": { "role": { "terseLabel": "Related party disclosures", "label": "Disclosure of related party [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r35" ] }, "moln_DisclosureOfRestructuringExpenseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfRestructuringExpenseTextBlock", "presentation": [ "http://www.molecularpartners.com/role/Restructuringexpense" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring expense", "label": "Disclosure Of Restructuring Expense [Text Block]", "documentation": "Disclosure Of Restructuring Expense" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRevenueExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Revenueandentitywidedisclosures" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue and entity-wide disclosures", "label": "Disclosure of revenue [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for revenue." } } }, "auth_ref": [ "r492" ] }, "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Contractliability" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liability", "label": "Disclosure of revenue from contracts with customers [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for revenue from contracts with customers." } } }, "auth_ref": [ "r91", "r92" ] }, "moln_DisclosureOfRoyaltiesAndLicenseFeesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfRoyaltiesAndLicenseFeesTextBlock", "presentation": [ "http://www.molecularpartners.com/role/Royaltiesandlicensefees" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties and license fees", "label": "Disclosure Of Royalties And License Fees [Text Block]", "documentation": "Disclosure Of Royalties And License Fees" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Shareholdersequity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity", "label": "Disclosure of share capital, reserves and other equity interest [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r183", "r256", "r288" ] }, "moln_DisclosureOfSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfSignificantAccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Significant Accounting Policies [Abstract]", "label": "Disclosure Of Significant Accounting Policies [Abstract]", "documentation": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]", "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r123", "r237" ] }, "moln_DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfTimingOfRevenueRecognitionByTypeOfPaymentsReceivedTableTextBlock", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Timing of Revenue Recognition by Type of Payments Received", "label": "Disclosure Of Timing Of Revenue Recognition By Type Of Payments Received [Table Text Block]", "documentation": "Disclosure Of Timing Of Revenue Recognition By Type Of Payments Received" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Tradeandotherpayables" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r492" ] }, "moln_DisclosureOfTradeAndOtherPayablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfTradeAndOtherPayablesLineItems", "presentation": [ "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Trade And Other Payables [Line Items]", "label": "Disclosure Of Trade And Other Payables [Line Items]", "documentation": "Disclosure Of Trade And Other Payables" } } }, "auth_ref": [] }, "moln_DisclosureOfTradeAndOtherPayablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfTradeAndOtherPayablesTable", "presentation": [ "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Trade And Other Payables [Table]", "label": "Disclosure Of Trade And Other Payables [Table]", "documentation": "Disclosure Of Trade And Other Payables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.molecularpartners.com/role/Tradeandotherreceivables" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other receivables", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r492" ] }, "moln_DisclosureOfTradeAndOtherReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfTradeAndOtherReceivablesLineItems", "presentation": [ "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Trade And Other Receivables [Line Items]", "label": "Disclosure Of Trade And Other Receivables [Line Items]", "documentation": "Disclosure Of Trade And Other Receivables [Line Items]" } } }, "auth_ref": [] }, "moln_DisclosureOfTradeAndOtherReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "DisclosureOfTradeAndOtherReceivablesTable", "presentation": [ "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Trade And Other Receivables [Table]", "label": "Disclosure Of Trade And Other Receivables [Table]", "documentation": "Disclosure Of Trade And Other Receivables [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://www.molecularpartners.com/role/RelatedpartydisclosuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure of Compensation Costs of Key Management", "label": "Disclosure of transactions between related parties [text block]" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]" } } }, "auth_ref": [ "r34", "r211" ] }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposals", "label": "Disposals, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r48", "r218" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposals", "label": "Disposals, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment including right-of-use assets resulting from disposals. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r471" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Accounting Standard", "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r360" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r359", "r360", "r383" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r359", "r360", "r383", "r426" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentInformationTable", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Registration Statement", "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r355" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Shell Company Report", "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r360" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r404" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r415" ] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "EUR", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails", "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails", "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofTradeReceivablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EUR", "verboseLabel": "EUR Positions", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings per share [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.molecularpartners.com/role/EarningspershareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Weighted Average Number of Shares Used in Computation", "label": "Earnings per share [text block]" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r39" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange (loss) gain on cash positions", "label": "Effect of exchange rate changes on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r61", "r62" ] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 7.0 }, "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Personnel expenses", "negatedTotalLabel": "Personnel expenses", "label": "Employee benefits expense" } } }, "auth_ref": [ "r179", "r262", "r296", "r347" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r357" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r357" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r468" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r357" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r466" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r357" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r357" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r467" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r409" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r462" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r462" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r462" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders' equity", "periodStartLabel": "Equity at beginning of period", "periodEndLabel": "Equity at end of period", "terseLabel": "Equity", "label": "Equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r70", "r72", "r83", "r84", "r85", "r212", "r228", "r251", "r252", "r260", "r276", "r284" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [abstract]", "label": "Equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders' equity and liabilities", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r276" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' equity and liabilities", "label": "Equity and liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_EquityInstrumentsAmountContributedToFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityInstrumentsAmountContributedToFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_PlanAssetsAtFairValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity instruments", "label": "Equity instruments, amount contributed to fair value of plan assets" } }, "en": { "role": { "documentation": "The amount instruments representing equity (rather than debt) contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [domain]]" } } }, "auth_ref": [ "r302", "r340" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r419" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r376", "r387", "r397", "r430" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r373", "r384", "r394", "r427" ] }, "ifrs-full_EstimateOfContributionsExpectedToBePaidToPlan": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EstimateOfContributionsExpectedToBePaidToPlan", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions by the employer", "label": "Estimate of contributions expected to be paid to plan for next annual reporting period" } }, "en": { "role": { "documentation": "The estimate of the expected contributions to be made to a defined benefit plan for the next annual reporting period. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r26", "r28", "r208" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r425" ] }, "moln_ExercisePriceOfOutstandingOtherEquityInstruments": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExercisePriceOfOutstandingOtherEquityInstruments", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of outstanding PSUs and RSUs (in CHF per share)", "label": "Exercise Price Of Outstanding Other Equity Instruments", "documentation": "Exercise Price Of Outstanding Other Equity Instruments" } } }, "auth_ref": [] }, "moln_ExercisePriceRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExercisePriceRangeOneMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price, range one", "label": "Exercise Price Range One [Member]", "documentation": "Exercise Price Range One" } } }, "auth_ref": [] }, "moln_ExpectedDividendOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExpectedDividendOtherEquityInstrumentsGranted", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend", "label": "Expected Dividend, Other Equity Instruments Granted", "documentation": "Expected Dividend, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "moln_ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExpectedVolatilityOnCommonSharesOtherEquityInstrumentsGranted", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility on Common shares", "label": "Expected Volatility On Common Shares, Other Equity Instruments Granted", "documentation": "Expected Volatility On Common Shares, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "moln_ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExpectedVolatilityOnNBIOtherEquityInstrumentsGranted", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility on NBI", "label": "Expected Volatility On NBI, Other Equity Instruments Granted", "documentation": "Expected Volatility On NBI, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "moln_ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExpectedVolatilityOnSPIOtherEquityInstrumentsGranted", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility on SPI", "label": "Expected Volatility On SPI, Other Equity Instruments Granted", "documentation": "Expected Volatility On SPI, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share-based compensation (non-cash effective)", "label": "Expense from share-based payment transactions" } } }, "auth_ref": [ "r125", "r238" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation (non-cash effective)", "label": "Expense from share-based payment transactions with employees" } } }, "auth_ref": [ "r496" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails", "http://www.molecularpartners.com/role/RestructuringexpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash cost for share-based payments", "label": "Expense from share-based payment transactions with parties other than employees" } } }, "auth_ref": [ "r496" ] }, "ifrs-full_ExpenseOfRestructuringActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseOfRestructuringActivities", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 3.0 }, "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult", "http://www.molecularpartners.com/role/RestructuringexpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restructuring expenses", "negatedTotalLabel": "Restructuring expenses", "terseLabel": "Expense of restructuring activities", "label": "Expense of restructuring activities" } } }, "auth_ref": [ "r295" ] }, "moln_ExpenseOfRestructuringActivitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExpenseOfRestructuringActivitiesMember", "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring expenses", "label": "Expense Of Restructuring Activities [Member]", "documentation": "Expense Of Restructuring Activities" } } }, "auth_ref": [] }, "moln_ExpiringIn2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExpiringIn2027Member", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Expiring In 2027 [Member]", "documentation": "Expiring In 2027" } } }, "auth_ref": [] }, "moln_ExpiringIn2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExpiringIn2028Member", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Expiring In 2028 [Member]", "documentation": "Expiring In 2028" } } }, "auth_ref": [] }, "moln_ExpiringIn2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExpiringIn2030Member", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2030", "label": "Expiring in 2030 [Member]", "documentation": "Expiring in 2030" } } }, "auth_ref": [] }, "moln_ExpiringIn2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExpiringIn2031Member", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2031", "label": "Expiring in 2031 [Member]", "documentation": "Expiring in 2031" } } }, "auth_ref": [] }, "moln_ExpiringIn2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ExpiringIn2032Member", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2032", "label": "Expiring in 2032 [Member]", "documentation": "Expiring in 2032" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 2.0 }, "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult", "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Finance costs", "label": "Finance costs" } } }, "auth_ref": [ "r292" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 1.0 }, "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult", "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial income", "totalLabel": "Finance income", "label": "Finance income" } } }, "auth_ref": [ "r504" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "totalLabel": "Net finance result", "label": "Finance income (cost)" } } }, "auth_ref": [ "r504" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets", "label": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r131", "r136", "r137", "r141", "r247", "r248", "r250", "r327" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets at amortized costs", "label": "Financial assets at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r148", "r241" ] }, "moln_FinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "FinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Financial Instruments [Abstract]", "documentation": "Financial Instruments [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r131" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities at amortized cost", "label": "Financial liabilities at amortised cost, category [member]" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r149", "r242" ] }, "moln_FinancialRiskManagementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "FinancialRiskManagementAbstract", "lang": { "en-us": { "role": { "label": "Financial Risk Management [Abstract]", "documentation": "Financial Risk Management [Abstract]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r380", "r391", "r401", "r434" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r380", "r391", "r401", "r434" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r380", "r391", "r401", "r434" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r380", "r391", "r401", "r434" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r380", "r391", "r401", "r434" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r414" ] }, "moln_FullContractualLifeOtherEquityInstruments": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "FullContractualLifeOtherEquityInstruments", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Full contractual life for RSU and PSU", "label": "Full Contractual Life, Other Equity Instruments", "documentation": "Full Contractual Life, Other Equity Instruments" } } }, "auth_ref": [] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "GBP", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails", "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GBP", "label": "United Kingdom, Pounds" } } }, "auth_ref": [] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Remeasurement of net pension liabilities", "negatedTerseLabel": "Actuarial (gain)/loss on defined benefit obligation", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r18", "r203" ] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyCountryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [axis]", "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r161", "r300", "r318", "r323", "r335" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyCountryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical areas [domain]", "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r161", "r300", "r318", "r323", "r335" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.molecularpartners.com/role/IntangibleassetsDetails", "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Gross carrying amount [member]" } } }, "auth_ref": [ "r6", "r46", "r55", "r58", "r126", "r137", "r141", "r194", "r216", "r224", "r227", "r248", "r250", "r327" ] }, "ifrs-full_GrossLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total contractual cash-flows", "label": "Gross lease liabilities" } }, "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r99", "r170", "r329" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r359", "r360", "r383" ] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income taxes", "label": "Tax expense (income)" } } }, "auth_ref": [ "r1", "r2", "r3", "r37", "r82", "r155", "r190", "r191", "r192", "r293" ] }, "moln_IncomeTaxesAndDeferredTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "IncomeTaxesAndDeferredTaxesAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes And Deferred Taxes [Abstract]", "documentation": "Income taxes [Abstract]" } } }, "auth_ref": [] }, "moln_IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "IncreaseDecreaseInAuthorizedShareCapitalEmployeeParticipation", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in authorized share capital, employee participation", "label": "Increase (Decrease) In Authorized Share Capital, Employee Participation", "documentation": "Increase (Decrease) In Authorized Share Capital, Employee Participation" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r66", "r185" ] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromAdministrationCostsNotReflectedInReturnOnPlanAssets", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Administrative cost (excl. cost for managing plan assets)", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from administration costs not reflected in return on plan assets" } } }, "auth_ref": [ "r473" ] }, "moln_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromCurtailment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromCurtailment", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Curtailment", "label": "Increase (Decrease) In Net Defined Benefit Liability (Asset) Resulting From Curtailment", "documentation": "Increase (Decrease) In Net Defined Benefit Liability (Asset) Resulting From Curtailment" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit cost recognized in profit or loss", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss" } } }, "auth_ref": [ "r473" ] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in number of shares outstanding", "label": "Increase (decrease) in number of shares outstanding" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r181", "r254", "r286" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfOptions", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of new shares under LTI plans", "label": "Increase (decrease) through exercise of options, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } } }, "auth_ref": [ "r494" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation costs", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r266" ] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares withheld to cover social security and tax", "label": "Increase (decrease) through treasury share transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r267" ] }, "moln_IncreaseDecreaseThroughVestingOfEquityInstrumentsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "IncreaseDecreaseThroughVestingOfEquityInstrumentsEquity", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of LTI plans", "label": "Increase (Decrease) Through Vesting Of Equity Instruments, Equity", "documentation": "Increase (Decrease) Through Vesting Of Equity Instruments, Equity" } } }, "auth_ref": [] }, "moln_IncreaseThroughNewLeasesAndLeaseExtensionOperatingLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "IncreaseThroughNewLeasesAndLeaseExtensionOperatingLeases", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease extension", "label": "Increase Through New Leases And Lease Extension, Operating Leases", "documentation": "Increase Through New Leases And Lease Extension, Operating Leases" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r380", "r391", "r401", "r425", "r434", "r438", "r446" ] }, "moln_IndividualsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "IndividualsAxis", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Individuals [Axis]", "label": "Individuals [Axis]", "documentation": "Individuals" } } }, "auth_ref": [] }, "moln_IndividualsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "IndividualsDomain", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Individuals [Domain]", "label": "Individuals [Domain]", "documentation": "Individuals [Domain]" } } }, "auth_ref": [] }, "moln_IndustryBenchmarkDiscountRatesPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "IndustryBenchmarkDiscountRatesPeriod", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rates based on industry benchmark, period", "label": "Industry Benchmark, Discount Rates, Period", "documentation": "Industry Benchmark, Discount Rates, Period" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r444" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r361", "r450" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r361", "r450" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r361", "r450" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition", "http://www.molecularpartners.com/role/IntangibleassetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "periodStartLabel": "Intangible assets at beginning of period", "periodEndLabel": "Intangible assets at end of period", "label": "Intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r50", "r220", "r272" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill [abstract]" } } }, "auth_ref": [] }, "moln_IntellectualPropertyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "IntellectualPropertyExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Intellectual property", "label": "Intellectual Property Expense", "documentation": "Intellectual Property Expense" } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense on defined benefit obligation", "label": "Interest expense, defined benefit plans" } } }, "auth_ref": [ "r472" ] }, "ifrs-full_InterestExpenseIncomeDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseIncomeDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof net interest expense on the net defined benefit liability", "label": "Interest expense (income), defined benefit plans" } } }, "auth_ref": [ "r472" ] }, "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expenses on defined benefit obligation", "negatedLabel": "Interest income on plan assets", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)" } } }, "auth_ref": [ "r16", "r202" ] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 }, "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails": { "parentTag": "moln_LeaseCostRecognisedInProfitOrLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails", "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails", "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense on leases", "verboseLabel": "Recognition of interest on lease liabilities", "terseLabel": "Interest expense on lease liabilities", "label": "Interest expense on lease liabilities" } } }, "auth_ref": [ "r97", "r168" ] }, "ifrs-full_InterestIncomeDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest income on plan assets", "label": "Interest income, defined benefit plans" } } }, "auth_ref": [ "r472" ] }, "ifrs-full_InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeForFinancialAssetsMeasuredAtAmortisedCost", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income on financial assets held at amortized costs", "label": "Interest revenue for financial assets measured at amortised cost" } } }, "auth_ref": [ "r128", "r244" ] }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest paid", "label": "Interest paid, classified as operating activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } } }, "auth_ref": [ "r63" ] }, "ifrs-full_InterestRateRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestRateRiskMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate risk", "label": "Interest rate risk [member]" } }, "en": { "role": { "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r108", "r109", "r110", "r111", "r152" ] }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Interest received", "label": "Interest received, classified as investing activities" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } } }, "auth_ref": [ "r63" ] }, "moln_IssuanceOfEquitySharesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "IssuanceOfEquitySharesAbstract", "lang": { "en-us": { "role": { "label": "Issuance of Equity Shares [Abstract]", "documentation": "Issuance of Equity Shares [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of new shares, net of transaction costs", "label": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r266" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r346", "r353" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share capital", "label": "Issued capital [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r268" ] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/RelatedpartydisclosuresDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/RelatedpartydisclosuresDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Key management personnel compensation costs", "label": "Key management personnel compensation" } } }, "auth_ref": [ "r33", "r210" ] }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/RelatedpartydisclosuresDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/RelatedpartydisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Post-employment benefits", "label": "Key management personnel compensation, post-employment benefits" } } }, "auth_ref": [ "r31" ] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/RelatedpartydisclosuresDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/RelatedpartydisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Key management personnel compensation, share-based payment" } } }, "auth_ref": [ "r32" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/RelatedpartydisclosuresDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/RelatedpartydisclosuresDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term employee benefits", "label": "Key management personnel compensation, short-term employee benefits" } } }, "auth_ref": [ "r30" ] }, "moln_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "LabEquipmentMember", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lab equipment", "label": "Lab Equipment [Member]", "documentation": "Lab Equipment" } } }, "auth_ref": [] }, "moln_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment:", "label": "Laboratory Equipment [Member]", "documentation": "Laboratory Equipment" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "More than 5 years", "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r101", "r102", "r113", "r173", "r176", "r328", "r330", "r332" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Between 1 and 2 years", "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r101", "r102", "r113", "r328", "r332", "r496" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Between 2 and 5 years", "label": "Later than two years and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than five years." } } }, "auth_ref": [ "r496" ] }, "moln_LeaseCostRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "LeaseCostRecognisedInProfitOrLoss", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofExpensesRecognisedinProfitorLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total amount recognized in profit or loss", "label": "Lease, Cost Recognised In Profit Or Loss", "documentation": "Lease, Cost Recognised In Profit Or Loss" } } }, "auth_ref": [] }, "moln_LeaseExtensionOrTerminationOptionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "LeaseExtensionOrTerminationOptionPeriod", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, extension or termination option, period", "label": "Lease, Extension Or Termination Option, Period", "documentation": "Lease, Extension Or Termination Option, Period" } } }, "auth_ref": [] }, "moln_LeaseExtensionTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "LeaseExtensionTermOfContract", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails", "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, extension term", "label": "Lease, Extension Term Of Contract", "documentation": "Lease, Extension Term Of Contract" } } }, "auth_ref": [] }, "moln_LeaseFacilitiesSchlierenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "LeaseFacilitiesSchlierenMember", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails", "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Facilities, Schlieren", "label": "Lease Facilities, Schlieren [Member]", "documentation": "Lease Facilities, Schlieren" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails", "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Lease liabilities at beginning of period", "periodEndLabel": "Lease liabilities at end of period", "totalLabel": "Lease liabilities", "terseLabel": "Carrying Amount lease liabilities", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_LeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities [abstract]", "label": "Lease liabilities [abstract]" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Lease liabilities [member]" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r312", "r313" ] }, "moln_LeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "LeaseTermOfContract", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, term", "label": "Lease, Term Of Contract", "documentation": "Lease, Term Of Contract" } } }, "auth_ref": [] }, "ifrs-full_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold improvements [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } } }, "auth_ref": [ "r469" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted market price", "label": "Level 1 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r22", "r43", "r44", "r84", "r214", "r252" ] }, "ifrs-full_Level2OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level2OfFairValueHierarchyMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-quoted market price", "label": "Level 2 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } } }, "auth_ref": [ "r43", "r44", "r84", "r214", "r252" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Levels of fair value hierarchy [axis]", "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r22", "r84", "r252" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Levels of fair value hierarchy [domain]", "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r22", "r84", "r252" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r83", "r84", "r85", "r156", "r159", "r251", "r252", "r276" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDeferredTaxesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net defined benefit liability", "periodStartLabel": "Net defined benefit liability at January 1", "periodEndLabel": "Defined benefit obligation at December 31", "negatedPeriodStartLabel": "Fair value of plan assets at January 1", "negatedPeriodEndLabel": "Fair value of plan assets at December 31", "terseLabel": "Net defined benefit liability (asset)", "label": "Net defined benefit liability (asset)" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r14", "r200" ] }, "moln_LicenseAndCollaborationAgreementWithNovartisAGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "LicenseAndCollaborationAgreementWithNovartisAGMember", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Novartis AG, Switzerland", "label": "License And Collaboration Agreement With Novartis AG [Member]", "documentation": "License And Collaboration Agreement With Novartis AG" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails", "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [axis]", "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r90", "r101", "r102", "r105", "r106", "r107", "r113", "r130", "r144", "r164", "r166", "r174", "r177", "r245", "r278", "r305", "r328" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails", "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity [domain]", "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r90", "r101", "r102", "r105", "r106", "r107", "r113", "r130", "r164", "r166", "r174", "r177", "r245", "r278", "r305", "r328", "r331" ] }, "ifrs-full_MaximumExposureToCreditRisk": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaximumExposureToCreditRisk", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum exposure to credit risk", "label": "Maximum exposure to credit risk" } }, "en": { "role": { "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]" } } }, "auth_ref": [ "r138" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r417" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r417" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r437" ] }, "moln_MolecularPartnersIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "MolecularPartnersIncMember", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Molecular Partners Inc.", "label": "Molecular Partners Inc. [Member]", "documentation": "Molecular Partners Inc." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r445" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r418" ] }, "moln_NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NegativeInterestRevenueForFinancialAssetsMeasuredAtAmortisedCost", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Negative interest on financial assets held at amortized costs", "label": "Negative Interest Revenue For Financial Assets Measured At Amortised Cost", "documentation": "Negative Interest Revenue For Financial Assets Measured At Amortised Cost" } } }, "auth_ref": [] }, "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetAxis", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net defined benefit liability (asset) [axis]", "label": "Net defined benefit liability (asset) [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r14", "r200" ] }, "ifrs-full_NetDefinedBenefitLiabilityAssetDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetDefinedBenefitLiabilityAssetDomain", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net defined benefit liability (asset) [domain]", "label": "Net defined benefit liability (asset) [domain]" } }, "en": { "role": { "documentation": "This member stands for the net defined benefit liability (asset). It also represents the standard value for the 'Net defined benefit liability (asset)' axis if no other member is used. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r14", "r200" ] }, "ifrs-full_NetForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net foreign exchange gain", "label": "Net foreign exchange gain" } } }, "auth_ref": [ "r480", "r498" ] }, "ifrs-full_NetForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NetForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net foreign exchange loss", "label": "Net foreign exchange loss" } } }, "auth_ref": [ "r480", "r498" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)" } } }, "auth_ref": [] }, "moln_NetOperatingLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NetOperatingLosses", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating losses", "label": "Net Operating Losses", "documentation": "Net Operating Losses" } } }, "auth_ref": [] }, "moln_NetOperatingProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NetOperatingProfit", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating profit", "label": "Net Operating Profit", "documentation": "Net Operating Profit" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "No trading symbol", "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r417" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r380", "r391", "r401", "r425", "r434" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r408" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r407" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r425" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r445" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r445" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [axis]", "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r189" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-adjusting events after reporting period [domain]", "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r189" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current assets", "label": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r75", "r279", "r314" ] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ContractliabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current contract liabilities", "label": "Non-current contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r87" ] }, "ifrs-full_NoncurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails": { "parentTag": "ifrs-full_LeaseLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition", "http://www.molecularpartners.com/role/LeasesDisclosureofMovementofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liability", "verboseLabel": "Non-current", "label": "Non-current lease liabilities" } }, "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r95" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r77", "r280", "r314" ] }, "ifrs-full_NoncurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentPayables", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables", "label": "Trade and other non-current payables" } }, "en": { "role": { "documentation": "The amount of non-current trade payables and non-current other payables. [Refer: Other non-current payables; Non-current trade payables]" } } }, "auth_ref": [ "r275" ] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits", "label": "Non-current provisions for employee benefits" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r259", "r283" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.molecularpartners.com/role/LeasesDisclosureofContractualMaturitiesofFinancialLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less than 1 year", "label": "Not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r101", "r102", "r113", "r172", "r175", "r277", "r328", "r332" ] }, "moln_NovartisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NovartisMember", "presentation": [ "http://www.molecularpartners.com/role/ContractliabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Novartis", "label": "Novartis [Member]", "documentation": "Novartis" } } }, "auth_ref": [] }, "moln_NovartisOptionAndEquityRightsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NovartisOptionAndEquityRightsAgreementMember", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Novartis Option and Equity Rights Agreement", "label": "Novartis Option And Equity Rights Agreement [Member]", "documentation": "Novartis Option And Equity Rights Agreement" } } }, "auth_ref": [] }, "moln_NumberOfBanksWhereDepositsAreHeld": { "xbrltype": "integerItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfBanksWhereDepositsAreHeld", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of banks where deposits are held", "label": "Number Of Banks Where Deposits Are Held", "documentation": "Number Of Banks Where Deposits Are Held" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Headcount at year end", "label": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r496" ] }, "moln_NumberOfFullTimeEquivalentEmployees": { "xbrltype": "decimalItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfFullTimeEquivalentEmployees", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeHeadCountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Full-time equivalents at year end", "label": "Number Of Full-Time Equivalent Employees", "documentation": "Number Of Full-Time Equivalent Employees" } } }, "auth_ref": [] }, "moln_NumberOfInstrumentsExercisedInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfInstrumentsExercisedInShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of instruments exercised (in shares)", "label": "Number Of Instruments Exercised In Share-Based Payment Arrangement", "documentation": "Number Of Instruments Exercised In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_NumberOfInstrumentsExpiredInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfInstrumentsExpiredInShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of instruments expired (in shares)", "label": "Number Of Instruments Expired In Share-Based Payment Arrangement", "documentation": "Number Of Instruments Expired In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfInstrumentsForfeitedInShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of instruments forfeited (in shares)", "label": "Number Of Instruments Forfeited In Share-Based Payment Arrangement", "documentation": "Number Of Instruments Forfeited In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": { "xbrltype": "decimalItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of instruments forfeited, performance adjustment (in shares)", "label": "Number Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved", "documentation": "Number Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of instruments granted (in shares)", "label": "Number of instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of instruments granted in share-based payment arrangement." } } }, "auth_ref": [ "r324", "r325", "r344" ] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of RSU and PSU granted (in shares)", "label": "Number of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r124", "r490" ] }, "moln_NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfInstrumentsOutstandingInShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of instruments outstanding, beginning of period (in shares)", "periodEndLabel": "Number of instruments outstanding, end of period (in shares)", "terseLabel": "Number of instruments outstanding (in shares)", "label": "Number Of Instruments Outstanding In Share-Based Payment Arrangement", "documentation": "Number Of Instruments Outstanding In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_NumberOfOperatingSegments1": { "xbrltype": "integerItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfOperatingSegments1", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesSegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number Of Operating Segments 1", "documentation": "Number Of Operating Segments 1" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of treasury shares vested under the program (in shares)", "negatedTerseLabel": "Number of PSU and RSU exercised (in shares)", "label": "Number of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r490" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of PSU and RSU expired (in shares)", "label": "Number of other equity instruments expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement." } } }, "auth_ref": [ "r490" ] }, "moln_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": { "xbrltype": "decimalItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of PSU and RSU forfeited, performance adjustment (in shares)", "label": "Number Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved", "documentation": "Number Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of PSU and RSU forfeited (in shares)", "label": "Number of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r490" ] }, "moln_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementInPercentageOfNumberGranted", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of PSUs issued, in percentage of number of PSUs granted", "label": "Number Of Other Equity Instruments Issued In Share-Based Payment Arrangement, In Percentage Of Number Granted", "documentation": "Number Of Other Equity Instruments Issued In Percentage Of Number Granted" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of PSUs and RSUs outstanding (in shares)", "periodStartLabel": "Number of PSU and RSU outstanding at beginning of period (in shares)", "periodEndLabel": "Number of PSU and RSU outstanding at end of period (in shares)", "label": "Number of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r490" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of share options outstanding at beginning of period (in shares)", "periodEndLabel": "Number of share options outstanding at end of period (in shares)", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r115", "r120", "r122", "r230", "r235" ] }, "ifrs-full_NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfPotentialOrdinarySharesThatAreAntidilutiveInPeriodPresented", "presentation": [ "http://www.molecularpartners.com/role/EarningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of potentially dilutive shares (in shares)", "label": "Number of potential ordinary shares that are antidilutive in period presented" } }, "en": { "role": { "documentation": "Number of potential ordinary shares that are antidilutive in the period presented." } } }, "auth_ref": [ "r481" ] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of share options exercised (in shares)", "label": "Number of share options exercised in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r118", "r233" ] }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of share options expired (in shares)", "label": "Number of share options expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } } }, "auth_ref": [ "r119", "r234" ] }, "moln_NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": { "xbrltype": "decimalItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of share options forfeited, performance adjustment (in shares)", "label": "Number Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved", "documentation": "Number Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Number of share options forfeited (in shares)", "label": "Number of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r117", "r232" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of share options granted (in shares)", "label": "Number of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r116", "r231" ] }, "moln_NumberOfSharesAuthorizedEmployeeParticipation": { "xbrltype": "sharesItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfSharesAuthorizedEmployeeParticipation", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized, employee participation (in shares)", "label": "Number Of Shares Authorized, Employee Participation", "documentation": "Number Of Shares Authorized, Employee Participation" } } }, "auth_ref": [] }, "moln_NumberOfSharesAuthorizedFinancingTransactions": { "xbrltype": "sharesItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfSharesAuthorizedFinancingTransactions", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized, financing transactions (in shares)", "label": "Number Of Shares Authorized, Financing Transactions", "documentation": "Number Of Shares Authorized, Financing Transactions" } } }, "auth_ref": [] }, "moln_NumberOfSharesIssuedInCapitalRaiseEquity": { "xbrltype": "sharesItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfSharesIssuedInCapitalRaiseEquity", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issued in relation to capital raise (in shares)", "label": "Number Of Shares Issued In Capital Raise, Equity", "documentation": "Number Of Shares Issued In Capital Raise, Equity" } } }, "auth_ref": [] }, "moln_NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity": { "xbrltype": "sharesItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfSharesIssuedInShareBasedPaymentArrangementsEquity", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued in relation to vesting of PSU and RSUs (in shares)", "label": "Number Of Shares Issued In Share Based Payment Arrangements, Equity", "documentation": "Number Of Shares Issued In Share Based Payment Arrangements, Equity" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails", "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares outstanding (in shares)", "periodStartLabel": "Shares in issue at start of period", "periodEndLabel": "Shares in issue at end of period", "label": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r181", "r254", "r286" ] }, "moln_NumberOfSharesWithheldToCoverSocialSecurityAndTaxLiabilities": { "xbrltype": "sharesItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfSharesWithheldToCoverSocialSecurityAndTaxLiabilities", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of treasury shares withheld to cover social security and tax liabilities (in shares)", "label": "Number Of Shares Withheld To Cover Social Security And Tax Liabilities", "documentation": "Number Of Shares Withheld To Cover Social Security And Tax Liabilities" } } }, "auth_ref": [] }, "moln_NumberOfShortTermTimeDepositPositions": { "xbrltype": "integerItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfShortTermTimeDepositPositions", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of short-term time deposit positions", "label": "Number Of Short-Term Time Deposit Positions", "documentation": "Number Of Short-Term Time Deposit Positions" } } }, "auth_ref": [] }, "moln_NumberOfVotesPerShare": { "xbrltype": "integerItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "NumberOfVotesPerShare", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of votes per share", "label": "Number Of Votes Per Share", "documentation": "Number Of Votes Per Share" } } }, "auth_ref": [] }, "ifrs-full_OccupancyExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OccupancyExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Facility expenses", "label": "Occupancy expense" } } }, "auth_ref": [ "r504" ] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails", "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment", "label": "Office equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r299" ] }, "ifrs-full_OperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OperatingExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total operating expenses", "label": "Operating expense" } } }, "auth_ref": [ "r504" ] }, "moln_OperatingExpenses1Abstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "OperatingExpenses1Abstract", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses 1 [Abstract]", "documentation": "Operating Expenses 1" } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.molecularpartners.com/role/Cover", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Ordinary shares, CHF 0.10 nominal value per share", "terseLabel": "Common shares", "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r503" ] }, "ifrs-full_OtherAssetsAmountContributedToFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAssetsAmountContributedToFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_PlanAssetsAtFairValue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Others", "label": "Other assets, amount contributed to fair value of plan assets" } }, "en": { "role": { "documentation": "The amount other types of assets not separately disclosed contribute to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [domain]]" } } }, "auth_ref": [ "r206", "r474" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive result, net of tax", "label": "Other comprehensive income" } } }, "auth_ref": [ "r79", "r265", "r290", "r294" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive result", "label": "Other comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange differences on translating foreign operations", "verboseLabel": "Exchange differences on translating foreign operations", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r281", "r294" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 }, "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement of net pension liabilities", "verboseLabel": "Remeasurement of net pension liabilities", "negatedTotalLabel": "Remeasurement of net pension liabilities", "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r281", "r294", "r472" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlansAbstract", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of amount recognized in OCI", "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans [abstract]" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r500" ] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/AccruedexpensesDetails": { "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AccruedexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r500" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other payables", "label": "Other current payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r500" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other current receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r345", "r352" ] }, "ifrs-full_OtherEmployeeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherEmployeeExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other personnel expenses", "label": "Other employee expense" } } }, "auth_ref": [ "r477" ] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/FinancialincomeandfinancialexpenseDisclosureofDetailedInformationaboutFinancialExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other financial expenses", "label": "Other finance cost" } } }, "auth_ref": [ "r496" ] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other financial expense", "label": "Other inflows (outflows) of cash, classified as operating activities" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r60" ] }, "moln_OtherNonEmployeeRelatedAccruedExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "OtherNonEmployeeRelatedAccruedExpensesMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-employee related accrued expenses", "label": "Other Non-Employee Related Accrued Expenses [Member]", "documentation": "Other Non-Employee Related Accrued Expenses" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r417" ] }, "moln_OtherResearchAndDevelopmentExpense1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "OtherResearchAndDevelopmentExpense1", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other research and development expenses", "label": "Other Research And Development Expense 1", "documentation": "Other Research And Development Expense 1" } } }, "auth_ref": [] }, "moln_OtherRestructuringExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "OtherRestructuringExpenses", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": "ifrs-full_ExpenseOfRestructuringActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other restructuring expenses", "label": "Other Restructuring Expenses", "documentation": "Other Restructuring Expenses" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r378", "r389", "r399", "r432" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r381", "r392", "r402", "r435" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r381", "r392", "r402", "r435" ] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Par value per share (in CHF per share)", "label": "Par value per share" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r180", "r253", "r285" ] }, "ifrs-full_PastServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PastServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Past service cost", "label": "Past service cost, defined benefit plans" } } }, "auth_ref": [ "r472" ] }, "ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PastServiceCostNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Past service cost", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from past service cost" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [domain]]" } } }, "auth_ref": [ "r19", "r204" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r406" ] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Transaction costs on issue of shares", "label": "Payments for share issue costs" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r485" ] }, "ifrs-full_PaymentsFromPlanNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsFromPlanNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Benefits (paid)/deposited", "terseLabel": "Benefits (paid)/deposited", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from payments from plan" } }, "en": { "role": { "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r21", "r205" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of lease liabilities", "label": "Payments of lease liabilities, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r311" ] }, "moln_PaymentsOfRestructuringActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PaymentsOfRestructuringActivities", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/RestructuringexpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of restructuring activities", "label": "Payments Of Restructuring Activities", "documentation": "Payments Of Restructuring Activities" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r416" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r416" ] }, "moln_PensionersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PensionersMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pensioners", "label": "Pensioners [Member]", "documentation": "Pensioners" } } }, "auth_ref": [] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r408" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r425" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r418" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r407" ] }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleDecreaseInActuarialAssumption", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Percentage of reasonably possible decrease in actuarial assumption", "label": "Percentage of reasonably possible decrease in actuarial assumption" } }, "en": { "role": { "documentation": "The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r24" ] }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of reasonably possible increase in actuarial assumption", "label": "Percentage of reasonably possible increase in actuarial assumption" } }, "en": { "role": { "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [domain]]" } } }, "auth_ref": [ "r24" ] }, "moln_PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PercentageOfVSAOContributionsInTotalCompanysDefinedBenefitPlans", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of VSAO contributions in total company's defined benefit plans", "label": "Percentage Of VSAO Contributions In Total Company's Defined Benefit Plans", "documentation": "Percentage Of VSAO Contributions In Company's Total Defined Benefit Contributions" } } }, "auth_ref": [] }, "moln_PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PerformanceShareUnitsPSUEmployeesExcludingManagementBoardMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share Units (PSU), Employees excluding Management Board", "label": "Performance Share Units (PSU), Employees Excluding Management Board [Member]", "documentation": "Performance Share Units (PSU), Employees Excluding Management Board" } } }, "auth_ref": [] }, "moln_PerformanceShareUnitsPSUManagementBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PerformanceShareUnitsPSUManagementBoardMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share Units (PSU), Management Board", "label": "Performance Share Units (PSU), Management Board [Member]", "documentation": "Performance Share Units (PSU), Management Board" } } }, "auth_ref": [] }, "moln_PerformanceShareUnitsPSUMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PerformanceShareUnitsPSUMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Share Units (PSU)", "label": "Performance Share Units (PSU) [Member]", "documentation": "Performance Share Units (PSU)" } } }, "auth_ref": [] }, "moln_PersonnelExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PersonnelExpensesAbstract", "lang": { "en-us": { "role": { "label": "Personnel Expenses [Abstract]", "documentation": "Personnel Expenses [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_PlanAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PlanAssetsAtFairValue", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_LiabilityAssetOfDefinedBenefitPlans", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of plan assets at December 31", "totalLabel": "Total plan assets at fair value at December 31", "label": "Plan assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r478" ] }, "ifrs-full_PlanAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PlanAssetsMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan assets", "label": "Plan assets [member]" } }, "en": { "role": { "documentation": "This member stands for defined benefit plan assets. Plan assets comprise: (a) assets held by a long-term employee benefit fund; and (b) qualifying insurance policies." } } }, "auth_ref": [ "r12", "r198" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r409" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r465" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r408" ] }, "moln_PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PostEmploymentBenefitCostAndShareBasedCompensationCostNonCashEffectiveCost", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pension and share-based compensation costs, non-cash portion", "label": "Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost", "documentation": "Post-Employment Benefit Cost And Share-Based Compensation Cost, Non-Cash Effective Cost" } } }, "auth_ref": [] }, "moln_PostEmploymentBenefitExpenseNonCashEffectivePensionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PostEmploymentBenefitExpenseNonCashEffectivePensionCost", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash effective pension costs", "label": "Post-Employment Benefit Expense, Non-Cash Effective Pension Cost", "documentation": "Post-Employment Benefit Expense, Non-Cash Effective Pension Cost" } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 }, "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Pension costs", "totalLabel": "Defined benefit cost recognized in profit or loss", "label": "Post-employment benefit expense in profit or loss, defined benefit plans" } } }, "auth_ref": [ "r472", "r477" ] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlansAbstract", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Components of defined benefit cost in profit or loss", "label": "Post-employment benefit expense in profit or loss, defined benefit plans [abstract]" } } }, "auth_ref": [] }, "ifrs-full_PotentialOrdinaryShareTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PotentialOrdinaryShareTransactionsMember", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential ordinary share transactions", "label": "Potential ordinary share transactions [member]" } }, "en": { "role": { "documentation": "This member stands for potential ordinary share transactions. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r297", "r338" ] }, "ifrs-full_PresentValueOfDefinedBenefitObligationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PresentValueOfDefinedBenefitObligationMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined benefit obligation", "label": "Present value of defined benefit obligation [member]" } }, "en": { "role": { "documentation": "This member stands for the present value of a defined benefit obligation. The present value of a defined benefit obligation is the present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods." } } }, "auth_ref": [ "r13", "r199" ] }, "ifrs-full_ProceedsFromExerciseOfOptions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfOptions", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from exercise of options", "label": "Proceeds from exercise of options" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of options." } } }, "auth_ref": [ "r485" ] }, "moln_ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ProceedsFromInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from investments in short-term time deposits", "label": "Proceeds From Investments In Short-Term Time Deposits, Classified As Investing Activities", "documentation": "Proceeds From Investments In Short-Term Time Deposits, Classified As Investing Activities" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of shares under LTI plans", "label": "Proceeds from issue of ordinary shares" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r485" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of new shares", "label": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r310" ] }, "moln_ProceedsFromVestingOfEquityInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ProceedsFromVestingOfEquityInstruments", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from vesting under the LTI plans", "label": "Proceeds From Vesting Of Equity Instruments", "documentation": "Proceeds From Vesting Of Equity Instruments" } } }, "auth_ref": [] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 }, "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows", "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "totalLabel": "Net result, attributable to shareholders", "terseLabel": "Net result attributable to shareholders", "verboseLabel": "Net result", "label": "Profit (loss)" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r71", "r73", "r156", "r157", "r213", "r229", "r264", "r289", "r314", "r321" ] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "totalLabel": "Result before income taxes", "label": "Profit (loss) before tax" } } }, "auth_ref": [ "r127", "r333", "r334", "r347", "r348" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "totalLabel": "Operating result", "label": "Profit (loss) from operating activities" } } }, "auth_ref": [ "r306", "r504" ] }, "ifrs-full_PropertyAmountContributedToFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyAmountContributedToFairValueOfPlanAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_PlanAssetsAtFairValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate funds", "label": "Real estate, amount contributed to fair value of plan assets" } }, "en": { "role": { "documentation": "The amount real estate contributes to the fair value of defined benefit plan assets. [Refer: Plan assets, at fair value; Defined benefit plans [domain]]" } } }, "auth_ref": [ "r304", "r342" ] }, "moln_PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PropertyOccupiedOrOtherAssetsUsedByEntityIncludedInFairValueOfPlanAssets", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof property occupied or other assets used by the entity", "label": "Property Occupied Or Other Assets Used By Entity Included In Fair Value Of Plan Assets", "documentation": "Property Occupied Or Other Assets Used By Entity Included In Fair Value Of Plan Assets" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition", "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "periodStartLabel": "Property, plant and equipment at beginning of period", "periodEndLabel": "Property, plant and equipment at end of period", "label": "Property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]" } } }, "auth_ref": [ "r94", "r471", "r499" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsAxis", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment including right-of-use assets [axis]", "label": "Property, plant and equipment including right-of-use assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r471" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssetsDomain", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment including right-of-use assets [domain]", "label": "Property, plant and equipment including right-of-use assets [domain]" } }, "en": { "role": { "documentation": "This member stands for a class of asset representing property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r471" ] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment", "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r8", "r196", "r307", "r320", "r337", "r343" ] }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of intangible assets", "label": "Purchase of intangible assets, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r309" ] }, "moln_PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "PurchaseOfInvestmentsInShortTermTimeDepositsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investments in short-term time deposits", "label": "Purchase Of Investments In Short-Term Time Deposits, Classified As Investing Activities", "documentation": "Purchase Of Investments In Short-Term Time Deposits, Classified As Investing Activities" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r309" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r406" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r406" ] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [axis]", "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r65", "r86", "r107", "r122", "r184", "r315", "r316", "r491" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [domain]", "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r65", "r86", "r107", "r122", "r184", "r315", "r316", "r491" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ranges of exercise prices for outstanding share options [axis]", "label": "Ranges of exercise prices for outstanding share options [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r122" ] }, "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ranges of exercise prices for outstanding share options [domain]", "label": "Ranges of exercise prices for outstanding share options [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]" } } }, "auth_ref": [ "r122" ] }, "moln_ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ReasonablyPossibleDecreaseInActuarialAssumptionsPeriod", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reasonably possible decrease in actuarial assumptions, period", "label": "Reasonably Possible Decrease In Actuarial Assumptions, Period", "documentation": "Reasonably Possible Decrease In Actuarial Assumptions, Period" } } }, "auth_ref": [] }, "moln_ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ReasonablyPossibleIncreaseInActuarialAssumptionsPeriod", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reasonably possible increase in actuarial assumptions, period", "label": "Reasonably Possible Increase In Actuarial Assumptions, Period", "documentation": "Reasonably Possible Increase In Actuarial Assumptions, Period" } } }, "auth_ref": [] }, "moln_ReconciliationOfDefinedBenefitObligationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ReconciliationOfDefinedBenefitObligationAbstract", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of defined benefit obligation", "label": "Reconciliation Of Defined Benefit Obligation [Abstract]", "documentation": "Reconciliation Of Defined Benefit Obligation" } } }, "auth_ref": [] }, "moln_ReconciliationOfFairValueOfPlanAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ReconciliationOfFairValueOfPlanAssetsAbstract", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of fair value of plan assets", "label": "Reconciliation Of Fair Value Of Plan Assets [Abstract]", "documentation": "Reconciliation Of Fair Value Of Plan Assets" } } }, "auth_ref": [] }, "moln_ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ReconciliationOfTheAmountRecognizedInTheStatementOfFinancialPositionAbstract", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of the amount recognized in the statement of financial position", "label": "Reconciliation Of The Amount Recognized In The Statement Of Financial Position [Abstract]", "documentation": "Reconciliation Of The Amount Recognized In The Statement Of Financial Position" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r373", "r384", "r394", "r427" ] }, "ifrs-full_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related party transactions [abstract]" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 1.0 }, "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research and development expenses", "terseLabel": "Research and development expense", "negatedTotalLabel": "Research and development expenses", "label": "Research and development expense" } } }, "auth_ref": [ "r52", "r222" ] }, "moln_ResearchAndDevelopmentExpense1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ResearchAndDevelopmentExpense1Member", "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails", "http://www.molecularpartners.com/role/RestructuringexpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research And Development Expense 1 [Member]", "documentation": "Research And Development Expense 1" } } }, "auth_ref": [] }, "moln_ResearchAndDevelopmentExpenseReimbursement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ResearchAndDevelopmentExpenseReimbursement", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense reimbursement", "label": "Research And Development Expense Reimbursement", "documentation": "Research And Development Expense Reimbursement" } } }, "auth_ref": [] }, "moln_ResearchConsumablesAndExternalResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ResearchConsumablesAndExternalResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Research consumables and external research and development expenses", "label": "Research Consumables And External Research And Development Expense", "documentation": "Research Consumables And External Research And Development Expense" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r374", "r385", "r395", "r428" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r375", "r386", "r396", "r429" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r382", "r393", "r403", "r436" ] }, "ifrs-full_RestrictedShareUnitsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestrictedShareUnitsMember", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted share units", "label": "Restricted share units [member]" } }, "en": { "role": { "documentation": "This member stands for restricted share units." } } }, "auth_ref": [ "r481" ] }, "moln_RestrictedShareUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "RestrictedShareUnitsRSUMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Share Units (RSU)", "label": "Restricted Share Units (RSU) [Member]", "documentation": "Restricted Share Units (RSU)" } } }, "auth_ref": [] }, "moln_RestructuringActivitiesNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "RestructuringActivitiesNumberOfPositionsEliminated", "presentation": [ "http://www.molecularpartners.com/role/RestructuringexpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of positions eliminated", "label": "Restructuring Activities, Number of Positions Eliminated", "documentation": "Restructuring Activities, Number of Positions Eliminated" } } }, "auth_ref": [] }, "moln_RestructuringExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "RestructuringExpenseAbstract", "lang": { "en-us": { "role": { "label": "Restructuring Expense [Abstract]", "documentation": "Restructuring Expense [Abstract]" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative losses", "label": "Retained earnings" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r346", "r353", "r354" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative losses", "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r268", "r349" ] }, "ifrs-full_ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReturnOnPlanAssetsExcludingInterestIncomeOrExpenseNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Return on plan assets excluding interest income", "label": "Return on plan assets excluding interest income or expense, net of tax, defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from the return on plan assets, excluding amounts included in interest expense (income) arising from defined benefit plans. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense]" } } }, "auth_ref": [ "r472" ] }, "ifrs-full_ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReturnOnPlanAssetsNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Return on plan assets excl. interest income", "label": "Decrease (increase) in net defined benefit liability (asset) resulting from return on plan assets excluding interest income or expense" } }, "en": { "role": { "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from the return on plan assets, excluding amounts included in interest income or expense. The return on plan assets is interest, dividends and other revenue derived from the plan assets, together with realised and unrealised gains or losses on the plan assets, less any costs of managing plan assets and less any tax payable by the plan itself, other than tax included in the actuarial assumptions used to measure the present value of the defined benefit obligation. [Refer: Plan assets [member]; Net defined benefit liability (asset); Actuarial assumptions [domain]; Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]" } } }, "auth_ref": [ "r17", "r203" ] }, "ifrs-full_RevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAbstract", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue [abstract]" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyCountryDetails", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenues from research and development collaborations", "terseLabel": "Total Revenues", "label": "Revenue from contracts with customers" } } }, "auth_ref": [ "r88", "r89", "r165" ] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Right-of-use assets [member]" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r93" ] }, "moln_RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "RiskFreeInterestRateCommonShareOtherEquityInstrumentsGranted", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate, common shares", "label": "Risk Free Interest Rate, Common Share, Other Equity Instruments Granted", "documentation": "Risk Free Interest Rate, Common Share, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "moln_RiskFreeInterestRateNBIOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "RiskFreeInterestRateNBIOtherEquityInstrumentsGranted", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate, NBI", "label": "Risk Free Interest Rate, NBI, Other Equity Instruments Granted", "documentation": "Risk Free Interest Rate, NBI, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "moln_RiskFreeInterestRateSPIOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "RiskFreeInterestRateSPIOtherEquityInstrumentsGranted", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate, SPI", "label": "Risk Free Interest Rate, SPI, Other Equity Instruments Granted", "documentation": "Risk Free Interest Rate, SPI, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "moln_RoyaltiesAndLicenseFeesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "RoyaltiesAndLicenseFeesExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": "ifrs-full_ResearchAndDevelopmentExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Royalties and license fees", "label": "Royalties And License Fees Expense", "documentation": "Royalties And License Fees Expense" } } }, "auth_ref": [] }, "moln_RoyaltiesMinimumAnnualAmountTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "RoyaltiesMinimumAnnualAmountTotal", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties, minimum amount required to pay in total", "label": "Royalties, Minimum Annual Amount, Total", "documentation": "Royalties, Minimum Annual Amount, Total" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r445" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r445" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r356" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r358" ] }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult": { "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0, "order": 2.0 }, "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/ConsolidatedStatementofProfitorLossandOtherComprehensiveResult" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Selling, general and administrative expenses", "negatedTotalLabel": "Selling, general and administrative expense", "label": "Selling, general and administrative expense" } } }, "auth_ref": [ "r504" ] }, "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SellingGeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.molecularpartners.com/role/AdditionalinformationonthenatureofexpensesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNonCashCostsforShareBasedPaymentsbyFunctionsDetails", "http://www.molecularpartners.com/role/RestructuringexpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, general and administrative expense [member]" } } }, "auth_ref": [ "r493", "r496" ] }, "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SensitivityAnalysisForEachTypeOfMarketRisk", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementTables" ], "lang": { "en-us": { "role": { "terseLabel": "Sensitivity Analysis to Reasonable Possible Change in Exchange Rates and Interest Rates", "label": "Sensitivity analysis for types of market risk [text block]" } }, "en": { "role": { "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]" } } }, "auth_ref": [ "r143" ] }, "moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariableEffectOnResultBeforeTax", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Effect on result before tax if interest rates decrease", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Effect On Result Before Tax" } } }, "auth_ref": [] }, "moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleDecreaseInRiskVariablePercent", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Decrease in exchange rates", "negatedLabel": "Decrease in interest rates", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Decrease In Risk Variable, Percent" } } }, "auth_ref": [] }, "moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariableEffectOnResultBeforeTax", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect on result before tax if exchange rates increase", "verboseLabel": "Effect on result before tax if interest rates increase", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Effect On Result Before Tax" } } }, "auth_ref": [] }, "moln_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent": { "xbrltype": "percentItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleIncreaseInRiskVariablePercent", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in exchange rates", "verboseLabel": "Increase in interest rates", "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent", "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Increase In Risk Variable, Percent" } } }, "auth_ref": [] }, "moln_ServiceCostAndAdministrativeCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ServiceCostAndAdministrativeCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDefinedBenefitPlanExpenseRecognizedinProfitorLossandOtherComprehensiveIncomeDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "thereof service cost and administrative cost", "label": "Service Cost And Administrative Cost, Defined Benefit Plans", "documentation": "Service Cost And Administrative Cost, Defined Benefit Plans" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types" } } }, "auth_ref": [] }, "moln_ShareOptionsPSUsAndRSUsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ShareOptionsPSUsAndRSUsMember", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PSU, RSU and options", "label": "Share Options, PSUs And RSUs [Member]", "documentation": "Share Options, PSUs And RSUs" } } }, "auth_ref": [] }, "moln_SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "SharePriceOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in CHF per share)", "label": "Share Price Of Other Equity Instruments Granted In Share-Based Payment Arrangement", "documentation": "Share Price Of Other Equity Instruments Granted In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_SharesOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "SharesOutstandingRollForward", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails", "http://www.molecularpartners.com/role/ShareholdersequitySharesIssuedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares Outstanding [Roll Forward]", "label": "Shares Outstanding [Roll Forward]", "documentation": "Shares Outstanding" } } }, "auth_ref": [] }, "moln_SharesWithheldToCoverSocialSecurityAndTaxLiabilitiesValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "SharesWithheldToCoverSocialSecurityAndTaxLiabilitiesValue", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total TCHF value, Shares withheld to cover social security and tax liabilities", "label": "Shares Withheld To Cover Social Security And Tax Liabilities, Value", "documentation": "Shares Withheld To Cover Social Security And Tax Liabilities, Value" } } }, "auth_ref": [] }, "moln_ShortTermTimeDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ShortTermTimeDepositsMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term time deposits", "label": "Short-Term Time Deposits [Member]", "documentation": "Short-Term Time Deposits" } } }, "auth_ref": [] }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails", "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term time deposits", "label": "Short-term deposits, not classified as cash equivalents" } }, "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r500" ] }, "ifrs-full_ShorttermEmployeeBenefitsAccruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermEmployeeBenefitsAccruals", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/AccruedexpensesDetails": { "parentTag": "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.molecularpartners.com/role/AccruedexpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll, bonuses and restructuring 2025", "label": "Short-term employee benefits accruals" } }, "en": { "role": { "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]" } } }, "auth_ref": [ "r502" ] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Social security costs", "label": "Social security contributions" } } }, "auth_ref": [ "r479" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [line items]", "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of changes in equity [table]", "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r268" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfIFRSCompliance": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfIFRSCompliance", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of preparation", "label": "Statement of IFRS compliance [text block]" } } }, "auth_ref": [ "r270" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r377", "r388", "r398", "r431" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "auth_ref": [] }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "lang": { "en-us": { "role": { "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r424" ] }, "moln_TaxLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "TaxLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDeferredTaxesDetails", "http://www.molecularpartners.com/role/IncomeTaxesDisclosureofExpiryofTaxLossCarryforwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax loss carryforwards", "negatedTerseLabel": "Tax loss carryforwards", "label": "Tax Loss Carryforwards", "documentation": "Tax Loss Carryforwards" } } }, "auth_ref": [] }, "moln_TaxLossCarryforwardsExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "TaxLossCarryforwardsExpirationPeriod", "presentation": [ "http://www.molecularpartners.com/role/IncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax loss carryforwards, expiration period", "label": "Tax Loss Carryforwards, Expiration Period", "documentation": "Tax Loss Carryforwards, Expiration Period" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r416" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r423" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition", "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other payables", "totalLabel": "Trade and other payables", "label": "Trade and other current payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r275" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofDetailedInformationaboutTradeandOtherPayablesDetails", "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Current trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r351", "r502" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition", "http://www.molecularpartners.com/role/TradeandotherreceivablesDisclosureofDetailedInformationaboutTradeandOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade and other receivables", "totalLabel": "Trade and other receivables", "label": "Trade and other current receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r258", "r273", "r282" ] }, "moln_TradePayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "TradePayablesMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialLiabilitiesatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade payables", "label": "Trade Payables [Member]", "documentation": "Trade Payables" } } }, "auth_ref": [] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.molecularpartners.com/role/FinancialinstrumentsDisclosureofFinancialAssetsatAmortizedCostDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables", "label": "Trade receivables [member]" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r135", "r140", "r246", "r249", "r327", "r496" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r444" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r446" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.molecularpartners.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r447" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r448" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r448" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r446" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r446" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r449" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r447" ] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofFinancialPosition", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury share reserve", "periodStartLabel": "Total TCHF value at beginning of period", "periodEndLabel": "Total TCHF value at end of period", "label": "Treasury shares" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r38", "r346", "r353" ] }, "ifrs-full_TreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TreasurySharesMember", "presentation": [ "http://www.molecularpartners.com/role/ConsolidatedStatementofChangesinEquity", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury share reserve", "verboseLabel": "Treasury shares", "label": "Treasury shares [member]" } }, "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r268" ] }, "moln_TreasurySharesNominalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "TreasurySharesNominalValue", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nominal value of treasury shares", "label": "Treasury Shares, Nominal Value", "documentation": "Treasury Shares, Nominal Value" } } }, "auth_ref": [] }, "moln_TreasurySharesTransactionCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "TreasurySharesTransactionCostsIncurred", "crdr": "debit", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs related to issuance of treasury shares", "label": "Treasury Shares, Transaction Costs Incurred", "documentation": "Treasury Shares, Transaction Costs Incurred" } } }, "auth_ref": [] }, "ifrs-full_TypesOfContractsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsAxis", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails", "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [axis]", "label": "Types of contracts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r319", "r322", "r336" ] }, "ifrs-full_TypesOfContractsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfContractsDomain", "presentation": [ "http://www.molecularpartners.com/role/LeasesNarrativeDetails", "http://www.molecularpartners.com/role/PropertyplantandequipmentDetails", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresDisclosureofRevenuebyMajorAlliancePartnerDetails", "http://www.molecularpartners.com/role/RevenueandentitywidedisclosuresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of contracts [domain]", "label": "Types of contracts [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } } }, "auth_ref": [ "r319", "r322", "r336" ] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [axis]", "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r29", "r108", "r109", "r110", "r112", "r129", "r133", "r134", "r209" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://www.molecularpartners.com/role/FinancialriskmanagementDisclosureofMaximumCreditRiskExposureDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of risks [domain]", "label": "Types of risks [domain]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r29", "r108", "r109", "r110", "r112", "r129", "r133", "r134", "r209" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [axis]", "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r123", "r237" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails", "http://www.molecularpartners.com/role/ShareholdersequityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Types of share-based payment arrangements [domain]", "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r123", "r237" ] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "USD", "presentation": [ "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsDisclosureofReconciliationofCashCashEquivalentsandShortTermTimeDepositsDetails", "http://www.molecularpartners.com/role/CashandcashequivalentsandshorttermtimedepositsNarrativeDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinExchangeRatesDetails", "http://www.molecularpartners.com/role/FinancialriskmanagementSensitivityAnalysistoReasonablePossibleChangeinInterestRatesDetails", "http://www.molecularpartners.com/role/TradeandotherpayablesDisclosureofTradePayablesDenominatedinOtherCurrencyExplanatoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "USD", "verboseLabel": "USD Positions", "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r443" ] }, "moln_UniversityOfZurichMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "UniversityOfZurichMember", "presentation": [ "http://www.molecularpartners.com/role/RoyaltiesandlicensefeesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "University of Zurich", "label": "University Of Zurich [Member]", "documentation": "University Of Zurich" } } }, "auth_ref": [] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable estimated useful lives, intangible assets", "label": "Useful life measured as period of time, intangible assets other than goodwill" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r45", "r215" ] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesDisclosureofUsefulLivesofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Applicable estimated useful lives, property, plant and equipment", "label": "Useful life measured as period of time, property, plant and equipment" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r5", "r193" ] }, "moln_VSAOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VSAOMember", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VSAO", "label": "VSAO [Member]", "documentation": "VSAO" } } }, "auth_ref": [] }, "moln_ValueOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "ValueOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement", "crdr": "credit", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total TCHF value, Shares vested under the program", "label": "Value Of Other Equity Instruments Exercised Or Vested In Share-Based Payment Arrangement", "documentation": "Value Of Other Equity Instruments Exercised Or Vested In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_VestingOfShareBasedPaymentArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VestingOfShareBasedPaymentArrangementAxis", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Of Share-Based Payment Arrangement [Axis]", "label": "Vesting Of Share-Based Payment Arrangement [Axis]", "documentation": "Vesting Of Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_VestingOfShareBasedPaymentArrangementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VestingOfShareBasedPaymentArrangementDomain", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Of Share-Based Payment Arrangement [Domain]", "label": "Vesting Of Share-Based Payment Arrangement [Domain]", "documentation": "Vesting Of Share-Based Payment Arrangement [Domain]" } } }, "auth_ref": [] }, "moln_VestingOfShareBasedPaymentArrangementTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VestingOfShareBasedPaymentArrangementTrancheOneMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Of Share-Based Payment Arrangement, Tranche One", "label": "Vesting Of Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "Vesting Of Share-Based Payment Arrangement, Tranche One" } } }, "auth_ref": [] }, "moln_VestingOfShareBasedPaymentArrangementTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VestingOfShareBasedPaymentArrangementTrancheThreeMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Of Share-Based Payment Arrangement, Tranche Three", "label": "Vesting Of Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Vesting Of Share-Based Payment Arrangement, Tranche Three" } } }, "auth_ref": [] }, "moln_VestingOfShareBasedPaymentArrangementTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VestingOfShareBasedPaymentArrangementTrancheTwoMember", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Of Share-Based Payment Arrangement, Tranche Two", "label": "Vesting Of Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Vesting Of Share-Based Payment Arrangement, Tranche Two" } } }, "auth_ref": [] }, "moln_VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementBlockingPeriod", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Blocking period", "label": "Vesting Requirements For Share-Based Payment Arrangement, Blocking Period", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Blocking Period" } } }, "auth_ref": [] }, "moln_VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementCliffVestingPeriod", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cliff vesting period", "label": "Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Period", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Cliff Vesting Period" } } }, "auth_ref": [] }, "moln_VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementNumberOfTranches", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of tranches", "label": "Vesting Requirements For Share-Based Payment Arrangement, Number Of Tranches", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Number Of Tranches" } } }, "auth_ref": [] }, "moln_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VestingRequirementsForShareBasedPaymentArrangementVestingPeriod", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesAdditionalInformationDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period", "documentation": "Vesting Requirements For Share-Based Payment Arrangement, Vesting Period" } } }, "auth_ref": [] }, "moln_VoluntaryComplementaryPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "VoluntaryComplementaryPlanMember", "presentation": [ "http://www.molecularpartners.com/role/SummaryofmaterialaccountingpoliciesEmployeeBenefitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Voluntary complementary plan", "label": "Voluntary Complementary Plan [Member]", "documentation": "Voluntary Complementary Plan" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r412" ] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofDetailedInformationaboutEmployeeExpensesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Salaries", "label": "Wages and salaries" } } }, "auth_ref": [ "r479" ] }, "ifrs-full_WeightedAverageDurationOfDefinedBenefitObligation2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageDurationOfDefinedBenefitObligation2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofNetDefinedBenefitLiabilityAssetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average duration of defined obligation in years at December 31", "label": "Weighted average duration of defined benefit obligation" } }, "en": { "role": { "documentation": "The weighted average duration of a defined benefit obligation. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r27" ] }, "moln_WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageExercisePriceOfInstrumentsExercisedInShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of instruments exercised (in CHF per share)", "label": "Weighted Average Exercise Price Of Instruments Exercised In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Instruments Exercised In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageExercisePriceOfInstrumentsExpiredInShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of instruments expired (in CHF per share)", "label": "Weighted Average Exercise Price Of Instruments Expired In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Instruments Expired In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of instruments forfeited (in CHF per share)", "label": "Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageExercisePriceOfInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of instruments forfeited, performance adjustment (in CHF per share)", "label": "Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved", "documentation": "Weighted Average Exercise Price Of Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved" } } }, "auth_ref": [] }, "moln_WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageExercisePriceOfInstrumentsGrantedInShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of instruments granted (in CHF per share)", "label": "Weighted Average Exercise Price Of Instruments Granted In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Instruments Granted In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "moln_WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageExercisePriceOfInstrumentsOutstandingInShareBasedPaymentArrangement", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price of instruments outstanding at beginning of period (in CHF per share)", "periodEndLabel": "Weighted average exercise price of instruments outstanding at end of period (in CHF per share)", "label": "Weighted Average Exercise Price Of Instruments Outstanding In Share-Based Payment Arrangement", "documentation": "Weighted Average Exercise Price Of Instruments Outstanding In Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of PSU and RSU exercised (in CHF per share)", "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r490" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of PSU and RSU expired (in CHF per share)", "label": "Weighted average exercise price of other equity instruments expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) expired in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r490" ] }, "moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of PSU and RSU forfeited, performance adjustment (in CHF per share)", "label": "Weighted Average Exercise Price Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved", "documentation": "Weighted Average Exercise Price Of Other Equity Instruments Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of PSU and RSU forfeited (in CHF per share)", "label": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r490" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails", "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price (in CHF per share)", "verboseLabel": "Weighted average exercise price of PSU and RSU granted (in CHF per share)", "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r490" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails", "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price of PSU and RSU outstanding at beginning of period (in CHF per share)", "periodEndLabel": "Weighted average exercise price of PSU and RSU outstanding at end of period (in CHF per share)", "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r490" ] }, "moln_WeightedAverageExercisePriceOfOtherEquityInstrumentsSharesWithheldToCoverSocialSecurityAndTaxLiabilitiesSharesWithheldToCoverSocialSecurityAndTaxLiabilities": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsSharesWithheldToCoverSocialSecurityAndTaxLiabilitiesSharesWithheldToCoverSocialSecurityAndTaxLiabilities", "presentation": [ "http://www.molecularpartners.com/role/ShareholdersequityDisclosureofTreasurySharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average price in CHF, Shares withheld to cover social security and tax liabilities (in CHF per share)", "label": "Weighted Average Exercise Price Of Other Equity Instruments, Shares Withheld To Cover Social Security And Tax Liabilities Shares Withheld To Cover Social Security And Tax Liabilities", "documentation": "Weighted Average Exercise Price Of Other Equity Instruments, Shares Withheld To Cover Social Security And Tax Liabilities Shares Withheld To Cover Social Security And Tax Liabilities" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of share options exercised (in CHF per share)", "label": "Weighted average exercise price of share options exercised in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r118", "r233" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of share options expired (in CHF per share)", "label": "Weighted average exercise price of share options expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r119", "r234" ] }, "moln_WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInShareBasedPaymentArrangementNonMarketPerformanceConditionsNotAchieved", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of share options forfeited, performance adjustment (in CHF per share)", "label": "Weighted Average Exercise Price Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved", "documentation": "Weighted Average Exercise Price Of Share Options Forfeited In Share-Based Payment Arrangement, Non-Market Performance Conditions Not Achieved" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of share options forfeited (in CHF per share)", "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r117", "r232" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average exercise price of share options granted (in CHF per share)", "label": "Weighted average exercise price of share options granted in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r116", "r231" ] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price of share options outstanding at beginning of period (in CHF per share)", "periodEndLabel": "Weighted average exercise price of share options outstanding at end of period (in CHF per share)", "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r115", "r120", "r230", "r235" ] }, "moln_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofConditionsandInputsUsedintheMeasurementoftheFairValuesatGrantDatesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value of rights granted (in CHF per share)", "label": "Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted", "documentation": "Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted" } } }, "auth_ref": [] }, "moln_WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments": { "xbrltype": "durationItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingOtherEquityInstruments", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofExercisePricesNumberandWeightedAverageRemainingContractualLifeofOutstandingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life of outstanding PSUs and RSUs", "label": "Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments", "documentation": "Weighted Average Remaining Contractual Life Of Outstanding Other Equity Instruments" } } }, "auth_ref": [] }, "moln_WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise": { "xbrltype": "perShareItemType", "nsuri": "http://www.molecularpartners.com/20251231", "localname": "WeightedAverageSharePriceInShareBasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise", "presentation": [ "http://www.molecularpartners.com/role/PersonnelexpensesDisclosureofMovementsintheNumberofAllIssuesRSUsPSUsandShareOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average share price, at date of exercise (in CHF per share)", "label": "Weighted Average Share Price In Share-Based Payment Arrangement Exercised During Period, At Date Of Exercise", "documentation": "Weighted Average Share Price In Share-Based Payment Arrangement Exercised During Period, At Date Of Exercise" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.molecularpartners.com/role/EarningspershareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares used in computing basic earnings per share (in shares)", "label": "Weighted average number of ordinary shares used in calculating basic earnings per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r41" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r410" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_a&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_b&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_d&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_f&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_g&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "143", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_143&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "145", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145_a&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_b&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "148", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_148_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_18&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_46&doctype=Standard", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2025-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53_g&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "58", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_58&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "59", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_59&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_125&doctype=Standard", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K_a&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_a&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_b&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115_f&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_119&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "128", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_128&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "170", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_170&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "180", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_180_b&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_c&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "204", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_204&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_a&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_b&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_c&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_d&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_f&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "208", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_208_d&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "209", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_209&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "211", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_211_b&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "223", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_223_f&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "227", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_227&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "230", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_230&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_a&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_i&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_v&doctype=Standard", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "34", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "56", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_56_b&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.49", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_51&doctype=Standard", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_b&doctype=Standard", "URIDate": "2025-03-27" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r297": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2025-03-27" }, "r298": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2025-03-27" }, "r299": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2025-03-27" }, "r300": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r301": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142_a&doctype=Standard", "URIDate": "2025-03-27" }, "r302": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142_b&doctype=Standard", "URIDate": "2025-03-27" }, "r303": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142_c&doctype=Standard", "URIDate": "2025-03-27" }, "r304": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142_d&doctype=Standard", "URIDate": "2025-03-27" }, "r305": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r306": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r307": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_127&doctype=Standard", "URIDate": "2025-03-27" }, "r308": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2025-03-27" }, "r309": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2025-03-27" }, "r310": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r311": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r312": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2025-03-27" }, "r313": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2025-03-27" }, "r314": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r315": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r316": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r317": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r318": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r319": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r320": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_53&doctype=Standard", "URIDate": "2025-03-27" }, "r321": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r322": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2025-03-27" }, "r323": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r324": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2025-03-27" }, "r325": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "IG23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_IG23&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r326": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r327": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r328": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r329": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11D", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r330": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r331": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r332": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r333": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r334": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r335": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r336": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_d&doctype=Standard", "URIDate": "2025-03-27" }, "r337": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "115", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_115&doctype=Standard", "URIDate": "2025-03-27" }, "r338": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "191", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_191_f&doctype=Standard", "URIDate": "2025-03-27" }, "r339": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "193", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_193_a&doctype=Standard", "URIDate": "2025-03-27" }, "r340": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "208", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_208_a&doctype=Standard", "URIDate": "2025-03-27" }, "r341": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "208", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_208_b&doctype=Standard", "URIDate": "2025-03-27" }, "r342": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "208", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_208_c&doctype=Standard", "URIDate": "2025-03-27" }, "r343": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "251", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_251&doctype=Standard", "URIDate": "2025-03-27" }, "r344": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_a&doctype=Standard", "URIDate": "2025-03-27" }, "r345": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r346": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r347": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r348": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r349": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r350": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_68&doctype=Standard", "URIDate": "2025-03-27" }, "r351": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r352": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r353": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r354": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r355": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r356": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r357": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r360": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r361": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r362": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r363": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r364": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r365": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r366": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r367": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r368": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r369": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r370": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r371": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r372": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r373": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r374": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r375": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r376": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r377": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r378": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r379": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r380": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r381": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r382": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r383": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r384": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r385": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r386": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r387": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r388": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r389": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r390": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r391": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r392": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r393": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r394": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r395": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r396": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r397": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r398": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r399": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r400": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r401": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r402": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r403": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r404": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r406": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r407": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r408": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r409": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r410": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r411": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r412": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r413": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r414": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r415": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r416": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r417": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r418": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r419": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r420": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r421": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r422": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r423": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r424": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r425": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r444": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r445": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r446": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r447": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r448": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r449": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r450": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r451": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r452": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141&doctype=Standard", "URIDate": "2025-03-27" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_144&doctype=Standard", "URIDate": "2025-03-27" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_145&doctype=Standard", "URIDate": "2025-03-27" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_5&doctype=Standard", "URIDate": "2025-03-27" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2025-03-27" }, "r479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2025-03-27" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2025-03-27" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }